Disease overview

Alterations

155

Molecular (A)

100

Clinical (B–E)

Direct drugs

459

Via biomarker

251

Natural agents

Natural products

112

Merged ranked

705

With trial/literature evidence

Sources: Seeds, Open Targets, HPO, ClinicalTrials.gov, DGIdb, ChEMBL, PubMed MeSH, PubMed Literature · Pipeline phase 7 · Updated 2026-07-05

Remission & chronicity

Spontaneous remission

Progressive and irreversible by definition; MMSE decline 1.07-3.4 points/year untreated; no spontaneous remission

Best-intervention remission

Cholinesterase inhibitors (donepezil, rivastigmine, galantamine) slow MMSE decline to 0.2-1.37 points/year — slowing, not stopping; lecanemab (anti-amyloid) reduced clinical decline rate by 27% at 18 months in early AD (CLARITY AD, 2022); donanemab showed 35% slowing in amyloid/tau positive group

Drug-free remission

—

Relapse after remission

—

Chronicity

—

Gap size

Small for symptom slowing; biological ceiling is genuinely low with current approaches

Primary barrier

biological

Barrier detail: True disease reversal or cure is not achievable with any current therapy; cholinesterase inhibitors have consistent but modest effects (average 2.7-point ADAS-Cog improvement vs placebo); anti-amyloid biologics represent a genuine mechanistic step forward but are not cures and have significant side effects (ARIA — amyloid-related imaging abnormalities in 21-36%)

Last SoC change: 2023 — FDA full approval of lecanemab (Leqembi) for early AD — first disease-modifying therapy; 2003 memantine added; cholinesterase inhibitors approved 1993-2001; aducanumab (2021) withdrawn after controversy; this represents the first genuine SOC change since early 2000s

Remission data layers: disease_db_100 · source-locked manual data · confidence: high

Identifiers: MONDO: MONDO:0004975 · EFO: EFO_0000249 · OMIM: 104300 · ORPHA: ORPHA:102 · MESH: D000544 · UMLS_CUI: C0002395

Alterations

155 total · Types A (molecular) through E (functional)

Name	Type	Subtype	Direction	Frequency	Evidence	Sources	Links
Abnormal social behavior	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Abnormal speech pattern	Functional	Functional	—	—	Moderate	HPO, Monarch	HPO
Abnormality of extrapyramidal motor function	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Abnormality of mental function	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Abnormality of vision	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Aggressive behavior	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Agitation	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Alzheimer disease	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Anomic aphasia	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Apathy	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Aphasia	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Apraxia	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Ataxia	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Babinski sign	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Cerebral amyloid angiopathy	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Cerebral cortex with spongiform changes	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Cerebral cortical atrophy	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Cognitive impairment	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Confusion	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Decreased circulating GABA concentration	Lab / Clinical	Lab value	—	—	Moderate	HPO, Monarch	HPO
Dementia	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Deposits immunoreactive to beta-amyloid protein	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Disinhibition	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Disturbed sensory perception	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Dysarthria	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Dysgraphia	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Dysphagia	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Dystonia	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Finger agnosia	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Gait disturbance	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Generalized-onset seizure	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Hallucinations	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Hypertonia	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Impairment of activities of daily living	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Intellectual disability	Functional	Functional test	—	—	Moderate	HPO, Monarch	HPO
Language impairment	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Long-tract sign	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Lower limb hyperreflexia	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Memory impairment	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Myoclonus	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Neurodevelopmental abnormality	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Neurofibrillary tangles	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Oculomotor apraxia	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Optic ataxia	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Parietal hypometabolism in FDG PET	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Parkinsonism	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Personality changes	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Seizure	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Semantic dementia	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Senile plaques	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Sleep-wake cycle disturbance	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Spastic tetraparesis	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Temporal cortical atrophy	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
ABCA1 ATP binding cassette subfamily A member 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ABCA7 ATP binding cassette subfamily A member 7	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ACE angiotensin I converting enzyme	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ACHE acetylcholinesterase (Yt blood group)	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ADAM10 ADAM metallopeptidase domain 10	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ADRA2A adrenoceptor alpha 2A	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ADRA2B adrenoceptor alpha 2B	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ADRA2C adrenoceptor alpha 2C	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
AKAP11 A-kinase anchoring protein 11	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
APH1B aph-1B gamma-secretase subunit	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
APOE apolipoprotein E	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
APP amyloid beta precursor protein	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ATP6V1A ATPase H+ transporting V1 subunit A	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ATP6V1B2 ATPase H+ transporting V1 subunit B2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ATP6V1C1 ATPase H+ transporting V1 subunit C1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
AURKA aurora kinase A	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
AURKB aurora kinase B	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
AXL AXL receptor tyrosine kinase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
Acceptability of the tDCS Treatment as Assessed by the tDCS Acceptability Questionnaire	Scales & PROs	Clinical scale	—	—	Emerging	ClinicalTrials.gov	—
BCHE butyrylcholinesterase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
BIN1 bridging integrator 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CAMLG calcium modulating ligand	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CD2AP CD2 associated protein	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CD33 CD33 molecule	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CDC25B cell division cycle 25B	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CDK1 cyclin dependent kinase 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CDK12 cyclin dependent kinase 12	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CDK4 cyclin dependent kinase 4	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CDK5 cyclin dependent kinase 5	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CDK5R1 cyclin dependent kinase 5 regulatory subunit 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CDKN1A cyclin dependent kinase inhibitor 1A	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CDKN1C cyclin dependent kinase inhibitor 1C	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CDKN2A cyclin dependent kinase inhibitor 2A	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CDKN2B cyclin dependent kinase inhibitor 2B	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CLK2 CDC like kinase 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CLU clusterin	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CR1 complement C3b/C4b receptor 1 (Knops blood group)	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CSNK1A1 casein kinase 1 alpha 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CTSB cathepsin B	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
DDX39B DExD-box helicase 39B	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
EPHA1 EPH receptor A1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
FADS2 fatty acid desaturase 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
FOXO3 forkhead box O3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GABRP gamma-aminobutyric acid type A receptor subunit pi	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GM2A ganglioside GM2 activator	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GRIN1 glutamate ionotropic receptor NMDA type subunit 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GRIN2A glutamate ionotropic receptor NMDA type subunit 2A	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GRIN2B glutamate ionotropic receptor NMDA type subunit 2B	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GRIN2C glutamate ionotropic receptor NMDA type subunit 2C	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GRIN2D glutamate ionotropic receptor NMDA type subunit 2D	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GRIN3A glutamate ionotropic receptor NMDA type subunit 3A	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GRIN3B glutamate ionotropic receptor NMDA type subunit 3B	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GRN granulin precursor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GSK3B glycogen synthase kinase 3 beta	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
H2BC4 H2B clustered histone 4	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
HFE homeostatic iron regulator	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
HMGCR 3-hydroxy-3-methylglutaryl-CoA reductase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
KAT8 lysine acetyltransferase 8	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
KIF1A kinesin family member 1A	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
LSM6 LSM6 homolog, U6 small nuclear RNA and mRNA degradation associated	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MASTL microtubule associated serine/threonine kinase like	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MPO myeloperoxidase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MS4A6A membrane spanning 4-domains A6A	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MTMR3 myotubularin related protein 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MTMR6 myotubularin related protein 6	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MTOR mechanistic target of rapamycin kinase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NCK2 NCK adaptor protein 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFA8 NADH:ubiquinone oxidoreductase subunit A8	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFA9 NADH:ubiquinone oxidoreductase subunit A9	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFAB1 NADH:ubiquinone oxidoreductase subunit AB1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFB7 NADH:ubiquinone oxidoreductase subunit B7	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFS1 NADH:ubiquinone oxidoreductase core subunit S1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFS2 NADH:ubiquinone oxidoreductase core subunit S2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFS5 NADH:ubiquinone oxidoreductase subunit S5	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFV2 NADH:ubiquinone oxidoreductase core subunit V2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NEU1 neuraminidase 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NR1H2 nuclear receptor subfamily 1 group H member 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
OGG1 8-oxoguanine DNA glycosylase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PI4KB phosphatidylinositol 4-kinase beta	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PIK3CB phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PIKFYVE phosphoinositide kinase, FYVE-type zinc finger containing	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PLCG2 phospholipase C gamma 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PLK1 polo like kinase 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PPT1 palmitoyl-protein thioesterase 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PSAP prosaposin	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PSEN1 presenilin 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PSEN2 presenilin 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
RIOK2 RIO kinase 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
SCARB1 scavenger receptor class B member 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
SCD stearoyl-CoA desaturase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
SLC18A2 solute carrier family 18 member A2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
SLC6A2 solute carrier family 6 member 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
SLC6A3 solute carrier family 6 member 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
SMPD1 sphingomyelin phosphodiesterase 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
SORL1 sortilin related receptor 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
Safety as Assessed by the Side Effects Questionnaire	Scales & PROs	Clinical scale	—	—	Emerging	ClinicalTrials.gov	—
TARS2 threonyl-tRNA synthetase 2, mitochondrial	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TGFBR2 transforming growth factor beta receptor 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TMEM106B transmembrane protein 106B	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TP53 tumor protein p53	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TREM2 triggering receptor expressed on myeloid cells 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
UQCRC1 ubiquinol-cytochrome c reductase core protein 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets

Therapeutics

Direct disease associations, biomarker-linked drugs, OSMF narrative-review natural agents, merged ranking, and clinical trial / literature evidence (top agents)

Drug	Type	Phase	Evidence	Score	Trials & literature	Sources	Links
INDOMETHACIN	Small molecule	Approved	Strong	105	3 Cochrane 2 Meta-analysis 2 Trial pubs 1 RCT View evidence Published literature Cochrane review Non-steroidal anti-inflammatory drugs as a treatment for Alzheimer's disease: a systematic review and meta-analysis of treatment effect (Drugs & aging, 2015) Cochrane review Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's disease (The Cochrane database of systematic reviews, 2012) Cochrane review Indomethacin for the treatment of Alzheimer's disease patients (The Cochrane database of systematic reviews, 2002) Clinical trial publication No effect of one-year treatment with indomethacin on Alzheimer's disease progression: a randomized controlled trial (PloS one, 2008) Clinical trial publication Clinical trial of indomethacin in Alzheimer's disease (Neurology, 1993) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
CIPROFLOXACIN	Small molecule	Approved	Strong	100	2 pubs View evidence CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
DONEPEZIL HYDROCHLORIDE	Small molecule	Approved	Strong	100	2 Meta-analysis 31 Trial pubs 23 RCT View evidence Published literature Meta-analysis The role of tonifying kidney decoction and acupuncture in the treatment of Alzheimer's disease: A network meta-analysis (Medicine, 2022) Meta-analysis A systematic review of the efficacy of donepezil hydrochloride combined with nimodipine on treating vascular dementia (Medicine, 2022) Clinical trial publication Effect of Social Restriction Due to the COVID-19 Pandemic on Activity of Daily Living and Disease Severity of Patients With Alzheimer Disease: Sub-analysis of a Double-blinded Noninferiority Study of Donepezil Patches and Donepezil Tablets (Alzheimer disease and associated disorders, 2025) Clinical trial publication Effect of Social Isolation Due to the COVID-19 Pandemic on Cognitive Dysfunction of Patients With Alzheimer Disease: Subanalysis of Double-blinded Noninferiority Study of Donepezil Patches and Donepezil Tablets (Alzheimer disease and associated disorders, 2024) Clinical trial publication Clinical observation on treatment of Alzheimer's disease with Sun's scalp-abdominal acupuncture combined with donepezil hydrochloride (Zhen ci yan jiu = Acupuncture research, 2024) Clinical trial publication Effects of pressing moxibustion at Baihui (GV 20) and Guanyuan (CV 4) on cognitive impairment and serum levels of Aβ(1-42), tau, P-tau in patients with mild to moderate Alzheimer's disease (Zhongguo zhen jiu = Chinese acupuncture & moxibustion, 2024) Clinical trial publication Effect of acupuncture at the acupoints for Yizhi Tiaoshen on the functional connectivity between the hippocampus and the brain in the patients with Alzheimer's disease (Zhongguo zhen jiu = Chinese acupuncture & moxibustion, 2023) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
FLORBETAPIR F 18	Small molecule	Approved	Strong	100	3 Trial pubs 3 RCT View evidence Published literature Clinical trial publication TRAILBLAZER-ALZ 4: A phase 3 trial comparing donanemab with aducanumab on amyloid plaque clearance in early, symptomatic Alzheimer's disease (Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025) Clinical trial publication A high-glycemic diet is associated with cerebral amyloid burden in cognitively normal older adults (The American journal of clinical nutrition, 2017) Clinical trial publication Physical Activity and Amyloid-β Brain Levels in Elderly Adults with Intact Cognition and Mild Cognitive Impairment (Journal of the American Geriatrics Society, 2015) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
GALANTAMINE HYDROBROMIDE	Small molecule	Approved	Strong	100	3 Trial pubs 3 RCT View evidence Published literature Clinical trial publication A prospective, double-blind, community-controlled comparison of three doses of galantamine in the treatment of mild to moderate Alzheimer's disease in a Korean population (Clinical therapeutics, 2004) Clinical trial publication The clinical efficacy and safety of galantamine in the treatment of Alzheimer's disease (CNS spectrums, 2004) Clinical trial publication The cognitive benefits of galantamine are sustained for at least 36 months: a long-term extension trial (Archives of neurology, 2004) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
MEMANTINE HYDROCHLORIDE	Small molecule	Approved	Strong	100	4 Trial pubs 3 RCT View evidence Published literature Clinical trial publication [Tolerability and efficacy of the long-term administration of memantine hydrochloride (Memary®) in patients with moderate to severe Alzheimer's disease] (Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics, 2014) Clinical trial publication Treatment with cholinesterase inhibitors and memantine of patients in the Alzheimer's Disease Neuroimaging Initiative (Archives of neurology, 2011) Clinical trial publication Investigation of the pharmacokinetic and pharmacodynamic interactions between memantine and glyburide/metformin in healthy young subjects: a single-center, multiple-dose, open-label study (Clinical therapeutics, 2005) Clinical trial publication Memantine hydrochloride: pharmacological and clinical profile (Drugs of today (Barcelona, Spain : 1998), 2004) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
NICOTINE	Small molecule	Approved	Strong	100	3 Cochrane 1 Meta-analysis 18 Trial pubs 10 RCT View evidence Published literature Cochrane review Features and outcomes of drugs for combination therapy as multi-targets strategy to combat Alzheimer's disease (Journal of ethnopharmacology, 2018) Cochrane review Efficacy and safety of nicotine on Alzheimer's disease patients (The Cochrane database of systematic reviews, 2001) Cochrane review Nicotine for Alzheimer's disease (The Cochrane database of systematic reviews, 2000) Meta-analysis [Smoking and neurological disorders] (Nihon rinsho. Japanese journal of clinical medicine, 2013) Systematic review Smoking and increased Alzheimer's disease risk: a review of potential mechanisms (Alzheimer's & dementia : the journal of the Alzheimer's Association, 2014) Clinical trial publication Radiofrequency fields, transthyretin, and Alzheimer's disease (Journal of Alzheimer's disease : JAD, 2010) Clinical trial publication PET imaging of the in vivo brain acetylcholinesterase activity and nicotine binding in galantamine-treated patients with AD (Neurobiology of aging, 2008) Clinical trial publication Changes in brain 11C-nicotine binding sites in patients with mild Alzheimer's disease following rivastigmine treatment as assessed by PET (Psychopharmacology, 2007) Clinical trial publication PET imaging of cortical 11C-nicotine binding correlates with the cognitive function of attention in Alzheimer's disease (Psychopharmacology, 2006) Clinical trial publication Nicotine and sensory memory in Alzheimer's disease: an event-related potential study (Brain and cognition, 2002) Randomized controlled trial Effects of transdermal nicotine on learning, memory, verbal fluency, concentration, and general health in a healthy sample at risk for dementia (International psychogeriatrics, 2001) Randomized controlled trial Effects of acute nicotine administration on cognitive event-related potentials in tacrine-treated and non-treated patients with Alzheimer's disease (Neuropsychobiology, 2002) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
PRAZOSIN	Small molecule	Approved	Strong	100	1 Cochrane 1 Trial pubs 1 RCT View evidence Published literature Cochrane review Risks and benefits of current and novel drugs to treat agitation in Alzheimer's disease (Expert opinion on drug safety, 2022) Clinical trial publication Prazosin for the treatment of behavioral symptoms in patients with Alzheimer disease with agitation and aggression (The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 2009) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
RIVASTIGMINE	Small molecule	Approved	Strong	100	42 Cochrane 45 Meta-analysis 163 Trial pubs 97 RCT View evidence Published literature Cochrane review Cost-effectiveness of traditional and novel neurotherapeutic agents for Alzheimer's disease: A systematic review (Journal of Alzheimer's disease : JAD, 2026) Cochrane review Comparative safety of cholinesterase inhibitors and memantine for dementia: a protocol for a network meta-analysis of randomized controlled trials (Systematic reviews, 2025) Cochrane review Rapid health technology assessment of galantamine for the treatment of Alzheimer's disease: A review (Medicine, 2025) Cochrane review Effects of rivastigmine on gait in patients with neurodegenerative disorders: A systematic review and meta-analysis (PloS one, 2024) Cochrane review Effect of long-term pharmacological treatments on Alzheimer disease: A systematic review and network meta-analysis (Medicine, 2024) Meta-analysis Bridging the gap: Efficacy of combined therapies for cognitive, behavioral, and functional outcomes in Alzheimer's disease - results from a systematic review and network meta-analysis (Journal of Alzheimer's disease : JAD, 2025) Meta-analysis Evaluating the efficacy and safety of Alzheimer's disease drugs: A meta-analysis and systematic review (Medicine, 2024) Meta-analysis Safety and efficacy of acetylcholinesterase inhibitors for Alzheimer's disease: A systematic review and meta-analysis (Advances in clinical and experimental medicine : official organ Wroclaw Medical University, 2024) Clinical trial publication Efficacy and safety of a novel, extended-release rivastigmine transdermal patch (TW-4752N) in patients with Alzheimer's disease: A 24-week randomized, double-blind trial with a 28-week open-label extension (Journal of Alzheimer's disease : JAD, 2026) Clinical trial publication Comparative Bioavailability Study of a Novel Multi-Day Patch Formulation of Rivastigmine (Twice Weekly) with Exelon® Transdermal Patch (Daily)- A Randomized Clinical Trial (Current Alzheimer research, 2022) Clinical trial publication Rivastigmine improves dual-task gait velocity in patients with Alzheimer's disease (BMC neurology, 2021) Clinical trial publication Sixteen-Week Interventional Study to Evaluate the Clinical Effects and Safety of Rivastigmine Capsules in Chinese Patients with Alzheimer's Disease (Journal of Alzheimer's disease : JAD, 2019) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
SIROLIMUS	Small molecule	Approved	Strong	100	1 Meta-analysis View evidence Published literature Meta-analysis Characterization of Altered Molecular Pathways in the Entorhinal Cortex of Alzheimer's Disease Patients and In Silico Prediction of Potential Repurposable Drugs (Genes, 2022) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
ACEBUTOLOL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ACETAZOLAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ACETYLCHOLINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
AMBENONIUM Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
AMBENONIUM CHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
AMPHETAMINE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
APIGENIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
APOMORPHINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
APRACLONIDINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
APRACLONIDINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ARGIPRESSIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ASENAPINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ASPIRIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ATENOLOL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ATIPAMEZOLE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ATORVASTATIN Repurposing	Small molecule	Approved	Strong	95	3 Cochrane 4 Meta-analysis 9 Trial pubs 8 RCT View evidence Published literature Cochrane review Effect of long-term pharmacological treatments on Alzheimer disease: A systematic review and network meta-analysis (Medicine, 2024) Cochrane review Statins for the treatment of dementia (The Cochrane database of systematic reviews, 2010) Cochrane review Statins for the prevention of dementia (The Cochrane database of systematic reviews, 2009) Meta-analysis The calcium-free form of atorvastatin inhibits amyloid-β(1-42) aggregation in vitro (The Journal of biological chemistry, 2022) Systematic review Alzheimer's Disease: Efficacy of Mono- and Combination Therapy. A Systematic Review (Journal of geriatric psychiatry and neurology, 2022) Clinical trial publication Atorvastatin May Correct Dyslipidemia in Adult Patients at Risk for Alzheimer's Disease Through an Anti-Inflammatory Pathway (CNS & neurological disorders drug targets, 2016) Clinical trial publication Effects of atorvastatin on cerebral blood flow in middle-aged adults at risk for Alzheimer's disease: a pilot study (Current Alzheimer research, 2012) Clinical trial publication Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe (Neurology, 2010) Clinical trial publication The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): design and baseline characteristics (Alzheimer's & dementia : the journal of the Alzheimer's Association, 2008) Clinical trial publication Change in circulating C-reactive protein is not associated with atorvastatin treatment in Alzheimer's disease (Neurological research, 2006) CT.gov search · Cochrane · PubMed	DGIdb	—
ATROPINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BENAZEPRIL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BENAZEPRIL HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BENAZEPRILAT Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BENZGALANTAMINE GLUCONATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BENZPHETAMINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BETAMETHASONE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BETAXOLOL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BETHANIDINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BICALUTAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
BISOPROLOL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BRIMONIDINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BRIMONIDINE TARTRATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BROMOCRIPTINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BUMETANIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BUPROPION HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CABERGOLINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CANDOXATRIL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CAPTOPRIL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CARBACHOL Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CARVEDILOL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CELIPROLOL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CHLORPROMAZINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CILAZAPRIL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CLOMIPRAMINE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CLONIDINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	2 Trial pubs 1 RCT View evidence Published literature Clinical trial publication Effects of Alzheimer's disease and normal aging on cerebrospinal fluid norepinephrine responses to yohimbine and clonidine (Archives of general psychiatry, 1995) Clinical trial publication Clonidine treatment of Alzheimer's disease (Archives of neurology, 1989) CT.gov search · Cochrane · PubMed	DGIdb	—
CLOPIDOGREL Repurposing	Small molecule	Approved	Strong	95	1 Trial pubs 1 RCT View evidence Published literature Clinical trial publication Effects of cilostazol on cognition and regional cerebral blood flow in patients with Alzheimer's disease and cerebrovascular disease: a pilot study (Geriatrics & gerontology international, 2013) CT.gov search · Cochrane · PubMed	DGIdb	—
CYCLOBENZAPRINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CYCLOSPORINE Repurposing	Small molecule	Approved	Strong	95	20 pubs View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
DAUNORUBICIN LIPOSOMAL Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
DEBRISOQUIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DEMECARIUM BROMIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DESERPIDINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DEXMEDETOMIDINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DEXTROAMPHETAMINE SULFATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DIAZEPAM Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DICHLORPHENAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DIETHYLSTILBESTROL Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DIPIVEFRIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DIPIVEFRIN HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
DISTIGMINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
DONEPEZIL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DONEPEZIL HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
DOPAMINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DOXAZOSIN MESYLATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DOXORUBICIN HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
DROXIDOPA Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ECHOTHIOPHATE IODIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ECOTHIOPATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
EDROPHONIUM CATION Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
EDROPHONIUM CHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ENALAPRIL MALEATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ENALAPRILAT Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ENALAPRILAT ANHYDROUS Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
EPHEDRINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
EPHEDRINE SULFATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
EPINEPHRINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
EPINEPHRINE BITARTRATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
EPIRUBICIN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ERGOLOID MESYLATES Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ERGOLOID MESYLATES, USP Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ERGOTAMINE TARTRATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ESMOLOL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ETHOXZOLAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ETOMIDATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
FENOFIBRATE MICRONIZED Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
FENOLDOPAM Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
FLUMAZENIL Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
FLUOXETINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
FOSINOPRIL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
FOSINOPRIL SODIUM Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
FUROSEMIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
GALANTAMINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
GALANTAMINE HYDROBROMIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
GUANABENZ Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
GUANABENZ ACETATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
GUANFACINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
GUANFACINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
HEXAFLUORENIUM BROMIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
HYDROCHLOROTHIAZIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
HYDROXYAMPHETAMINE HYDROBROMIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ILOPERIDONE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
IMIDAPRIL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
IMIPRAMINE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
INDAPAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
INDOMETHACIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ISOFLUROPHATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ISOPROTERENOL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ISOSORBIDE DINITRATE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
LABETALOL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
LABETALOL HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
LEVONORDEFRIN Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
LISINOPRIL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
LISINOPRIL ANHYDROUS Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
LOFEXIDINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
LOFEXIDINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
LURASIDONE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
MAFENIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
MAGNESIUM CHLORIDE ANHYDROUS Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
MALATHION Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
MECAMYLAMINE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
MEPERIDINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
MEPHENTERMINE SULFATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
METHADONE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
METHAMPHETAMINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
METHAZOLAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
METHOXSALEN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
METHYLDOPA ANHYDROUS Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
METHYLDOPATE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
METOPROLOL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
METOPROLOL Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
MIANSERIN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
MILNACIPRAN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
MINAPRINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
MINAPRINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
MIRTAZAPINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
MOEXIPRIL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
MOEXIPRIL HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
MOXISYLYTE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
MOXONIDINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
NADOLOL Repurposing	Small molecule	Approved	Strong	95	1 pubs View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
NALIDIXIC ACID Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
NAPHAZOLINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
NAPHAZOLINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
NEBIVOLOL HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
NEOSTIGMINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
NEOSTIGMINE METHYLSULFATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
NIROGACESTAT Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
NIROGACESTAT HYDROBROMIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
NITROPRUSSIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
NOREPINEPHRINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
NOREPINEPHRINE BITARTRATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
NORFLOXACIN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
NORTRIPTYLINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
OFLOXACIN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
OLANZAPINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
OXYMETAZOLINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
OXYMETAZOLINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
PERGOLIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
PERINDOPRIL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
PERINDOPRIL ARGININE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
PERINDOPRIL ERBUMINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
PERINDOPRILAT Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
PHENOXYBENZAMINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
PHENOXYBENZAMINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
PHENTOLAMINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
PHENTOLAMINE MESYLATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
PHENYLPROPANOLAMINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
PHENYTOIN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
PHYSOSTIGMINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
PHYSOSTIGMINE SALICYLATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
PINDOLOL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
PRALIDOXIME CATION Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
PRALIDOXIME CHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
PRASUGREL Repurposing	Small molecule	Approved	Strong	95	1 pubs View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
PRAVASTATIN SODIUM Repurposing	Small molecule	Approved	Strong	95	1 Trial pubs View evidence Published literature Clinical trial publication Reduction in levels of 24S-hydroxycholesterol by statin treatment in patients with Alzheimer disease (Archives of neurology, 2003) CT.gov search · Cochrane · PubMed	DGIdb	—
PRAZOSIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
PROBUCOL Repurposing	Small molecule	Approved	Strong	95	1 Trial pubs 1 RCT View evidence Published literature Clinical trial publication Effects of Probucol on plasma amyloid-β transport in patients with hyperlipidemia: a 12-week randomized, double-blind, placebo-controlled trial (Lipids in health and disease, 2024) CT.gov search · Cochrane · PubMed	DGIdb	—
PROPANIDID Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
PROPRANOLOL HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
PROPYLHEXEDRINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
PSEUDOEPHEDRINE POLISTIREX Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
PYRIDOSTIGMINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
PYRIDOSTIGMINE BROMIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
QUINAPRIL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
QUINAPRIL HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
QUINAPRILAT Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
RACEPINEPHRINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
RAMIPRIL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
RAMIPRILAT Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
RAUWOLFIA SERPENTINA Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
RAUWOLFIA SERPENTINA (USP) Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
REMIFENTANIL HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
RESCINNAMINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
RILMENIDINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
RISPERIDONE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
RIVASTIGMINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
RIVASTIGMINE TARTRATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ROSUVASTATIN Repurposing	Small molecule	Approved	Strong	95	1 Cochrane 1 Meta-analysis View evidence Published literature Cochrane review Statins for the prevention of dementia (The Cochrane database of systematic reviews, 2009) CT.gov search · Cochrane · PubMed	DGIdb	—
SILDENAFIL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
SIMVASTATIN Repurposing	Small molecule	Approved	Strong	95	6 Cochrane 4 Meta-analysis 16 Trial pubs 9 RCT View evidence Published literature Cochrane review Statins for the prevention of dementia (The Cochrane database of systematic reviews, 2016) Cochrane review Statins for the treatment of dementia (The Cochrane database of systematic reviews, 2010) Cochrane review Can statins prevent or help treat Alzheimer's disease? (Journal of Alzheimer's disease : JAD, 2010) Cochrane review Statins for the prevention of dementia (The Cochrane database of systematic reviews, 2009) Cochrane review Statins for the prevention of Alzheimer's disease (The Cochrane database of systematic reviews, 2001) Meta-analysis Evidence for benefit of statins to modify cognitive decline and risk in Alzheimer's disease (Alzheimer's research & therapy, 2017) Clinical trial publication Effects of Simvastatin on Plasma Amyloid-β Transport in Patients with Hyperlipidemia: A 12-Week Randomized, Double-Blind, Placebo-Controlled Trial (Journal of Alzheimer's disease : JAD, 2022) Clinical trial publication Effect of simvastatin on CSF Alzheimer disease biomarkers in cognitively normal adults (Neurology, 2017) Clinical trial publication Simvastatin ameliorate memory deficits and inflammation in clinical and mouse model of Alzheimer's disease via modulating the expression of miR-106b (Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2017) Clinical trial publication LDL-lipids from patients with hypercholesterolaemia and Alzheimer's disease are inflammatory to microvascular endothelial cells: mitigation by statin intervention (Clinical science (London, England : 1979), 2015) Clinical trial publication Longitudinal plasma amyloid beta in Alzheimer's disease clinical trials (Alzheimer's & dementia : the journal of the Alzheimer's Association, 2015) Randomized controlled trial Toward onset prevention of cognitive decline in adults with Down syndrome (the TOP-COG study): study protocol for a randomized controlled trial (Trials, 2014) CT.gov search · Cochrane · PubMed	DGIdb	—
SODIUM CHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
SOTALOL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
SPIRAPRIL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
SPIRAPRIL HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
SULBACTAM Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
TACRINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
TACRINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
TACROLIMUS ANHYDROUS Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
TAZOBACTAM Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
TETRAHYDROZOLINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
TETRAHYDROZOLINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
THIOGUANINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
TIZANIDINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
TIZANIDINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
TOLAZOLINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
TOLAZOLINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
TORSEMIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
TRANDOLAPRIL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
TRANDOLAPRILAT Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
TRAZODONE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
TROGLITAZONE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
VORINOSTAT Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
XYLAZINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
XYLOMETAZOLINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
XYLOMETAZOLINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
YOHIMBINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ACETYLCYSTEINE	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
ARIPIPRAZOLE	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
BREXPIPRAZOLE	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
CRENEZUMAB	Biologic	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
DEXTROMETHORPHAN	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
DOCONEXENT	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
DOXYCYCLINE	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
ESCITALOPRAM	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
FOLIC ACID	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
GANTENERUMAB	Biologic	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
HALOPERIDOL	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
IBUPROFEN	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
LATREPIRDINE	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
LEUPROLIDE ACETATE	Biologic	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
LIRAGLUTIDE	Biologic	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
MODAFINIL	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
NIACINAMIDE	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
NILVADIPINE	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
PREDNISONE	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
RIFAMPIN	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
RISPERIDONE	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
ROTIGOTINE	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
SEMAGACESTAT	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
SEMAGLUTIDE	Biologic	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
SERINE	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
SOLANEZUMAB	Biologic	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
SUVOREXANT	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
TRICAPRILIN	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
UDENAFIL	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
VITAMIN E	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
XALIPRODEN	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
ALPHA-TOCOPHEROL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ATORVASTATIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
AZELIRAGON	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
BAPINEUZUMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
BARICITINIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
BEZISTERIM	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
BUNTANETAP	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
BUPROPION	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CELECOXIB	Small molecule	Phase III	Moderate	80	—	Open Targets, ChEMBL	ChEMBL Open Targets
CHEMBL109	Small molecule	Phase III	Moderate	80	—	ChEMBL	ChEMBL Open Targets
CHEMBL113	Small molecule	Phase III	Moderate	80	—	ChEMBL	ChEMBL Open Targets
CHEMBL1200711	Small molecule	Phase III	Moderate	80	—	ChEMBL	ChEMBL Open Targets
CHEMBL1200806	Small molecule	Phase III	Moderate	80	—	ChEMBL	ChEMBL Open Targets
CHEMBL1536	Small molecule	Phase III	Moderate	80	—	ChEMBL	ChEMBL Open Targets
CHEMBL218166	Small molecule	Phase III	Moderate	80	—	ChEMBL	ChEMBL Open Targets
CHEMBL542541	Small molecule	Phase III	Moderate	80	—	ChEMBL	ChEMBL Open Targets
CHOLECALCIFEROL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CITALOPRAM	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CROMOLYN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CYANOCOBALAMIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
DEUDEXTROMETHORPHAN HYDROBROMIDE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ELENBECESTAT	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ENCENICLINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ENCENICLINE HYDROCHLORIDE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ESTROGENS, CONJUGATED	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
GALANTAMINE	Small molecule	Phase III	Moderate	80	—	Open Targets, ChEMBL	ChEMBL Open Targets
GUANFACINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
HYDRALAZINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
HYDROMETHYLTHIONINE MESYLATE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ICOSAPENT	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
IDALOPIRDINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
INTEPIRDINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
LANABECESTAT	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
LEVONORGESTREL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
MASITINIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
MEMANTINE	Small molecule	Phase III	Moderate	80	—	Open Targets, ChEMBL	ChEMBL Open Targets
METHYLPHENIDATE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
MIRTAZAPINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
NABILONE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
NILOTINIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
OCTAHYDROAMINOACRIDINE SUCCINATE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
PEXIDARTINIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
PHENSERINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
PROGESTERONE	Small molecule	Phase III	Moderate	80	—	Open Targets, ChEMBL	ChEMBL Open Targets
PYRIDOXINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
QUINIDINE SULFATE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
REMTERNETUG	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ROSIGLITAZONE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
SIMUFILAM	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
SIMVASTATIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TARENFLURBIL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TAVILERMIDE	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TERTOMOTIDE	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TESTOSTERONE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TIRAPAZAMINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TRAMIPROSATE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TRAZODONE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TRONTINEMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TROSPIUM CHLORIDE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
VALILTRAMIPROSATE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
VERUBECESTAT	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
XANOMELINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ZANAPEZIL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ZOLPIDEM	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ZOPICLONE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
DARAPLADIB Repurposing	Small molecule	Phase III	Moderate	70	—	ChEMBL	ChEMBL Open Targets
FENRETINIDE Repurposing	Small molecule	Phase III	Moderate	70	—	ChEMBL	ChEMBL Open Targets
ACITRETIN	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
ARGININE	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
ATOMOXETINE HYDROCHLORIDE	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
ATORVASTATIN CALCIUM	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
AVAGACESTAT	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
BENFOTIAMINE	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
BEXAROTENE	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
CERLAPIRDINE	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
DIVALPROEX SODIUM	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
ESTRADIOL	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
ICOSAPENT ETHYL	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
INOSITOL	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
LAMIVUDINE	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
LEVETIRACETAM	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
LITHIUM CARBONATE	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
LORNOXICAM	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
MEDROXYPROGESTERONE ACETATE	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
MIFEPRISTONE	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
NAPROXEN	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
NEFIRACETAM	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
PERINDOPRIL	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
PONEZUMAB	Biologic	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
POZANICLINE	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
PRAMIPEXOLE	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
RIFAXIMIN	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
RILUZOLE	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
ROFECOXIB	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
SAPROPTERIN	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
SARACATINIB	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
TAMIBAROTENE	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
TELMISARTAN	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
THALIDOMIDE	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
THIETHYLPERAZINE	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
2,4-DINITROPHENOL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
2-HYDROXYPROPYL-BETA-CYCLODEXTRIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ABT-126	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ABT-288	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ABT-384	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ABT-418	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ACAMPROSATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ADENOSINE TRIPHOSPHATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ALBUMIN HUMAN	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ALDESLEUKIN	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
AMILOMOTIDE	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
AMLODIPINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
AQW051	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ARUNDIC ACID	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ASPIRIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ATABECESTAT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ATUZAGINSTAT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
AZD0328	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
AZD1446	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BACLOFEN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BASMISANIL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BEPRANEMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BLARCAMESINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BLARCAMESINE HYDROCHLORIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BREXANOLONE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BRYOSTATIN 1	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BUMETANIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CANAKINUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CANDESARTAN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CANNABIDIOL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CEPEROGNASTAT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CERLAPIRDINE HYDROCHLORIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CINHYALURONATE SODIUM	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CLOPIDOGREL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
COLURACETAM	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CORT 108297	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CX516	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DALZANEMDOR	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DARATUMUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DASATINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DAVUNETIDE	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DB959	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DEFERIPRONE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DEXTROMETHORPHAN HYDROBROMIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DIMETHYL FUMARATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DRONABINOL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
EDELINONTRINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ELTOPRAZINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
EMAPUNIL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
EMESTEDASTAT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
EMPAGLIFLOZIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ENRUPATINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
EPIGALOCATECHIN GALLATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ETALANETUG	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ETAZOLATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
EXENATIDE	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
FACINICLINE HYDROCHLORIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
FASUDIL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
FERULATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
FILGRASTIM	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
FK-962	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
FLUTAFURANOL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
FORALUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
FORMOTEROL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
FOSGONIMETON	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GINKGO	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GOSURANEMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GSK239512	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GTS-21	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
IBUTAMOREN MESYLATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ICAPAMESPIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
IMD-1041	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
INSULIN DETEMIR	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
INSULIN GLULISINE	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
INSULIN HUMAN	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
INTERFERON BETA-1A	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
IPENOXAZONE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ISMIDENON	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ISOFLAVONE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ISPRONICLINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LADOSTIGIL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LANDIPIRDINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LECOZOTAN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LECOZOTAN HYDROCHLORIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LEMBOREXANT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LENALIDOMIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LENOGRASTIM	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LERONLIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LOSARTAN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LY-2886721	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MARITUPIRDINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MASUPIRDINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MELATONIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
METHANESULFONYL FLUORIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
METHYLENE BLUE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
METHYLENE BLUE ANHYDROUS	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
METHYLINOSITOL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MEVIDALEN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MIBAMPATOR	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MINOCYCLINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MITOGLITAZONE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MK-0249	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MK-0752	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MK-7622	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MONTELUKAST	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MW-150	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
NEFLAMAPIMOD	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
NICOTINAMIDE RIBOSIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
NIROGACESTAT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
NITROUS OXIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
OBICETRAPIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
OLEOYLESTRONE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
OMEGA-3 FATTY ACIDS	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ORM-12741	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
OSORESNONTRINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
OSUGACESTAT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
OZANIMOD	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PALIRODEN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PEGFILGRASTIM	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PEGIPANERMIN	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PEGSEBRENATIDE	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PF-05212377	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PIMAVANSERIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PIMAVANSERIN TARTRATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PIOGLITAZONE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PIROMELATINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PLASMINOGEN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
POSDINEMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PRX-03140	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
QS-21	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
QUERCETIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
QUINIDINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RALOXIFENE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RAMELTEON	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RASAGILINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RESEQUINIL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RESVERATROL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RILAPLADIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SABIRNETUG	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SARGRAMOSTIM	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SCYLLITOL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SELTOREXANT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SEMBRAGILINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SEMORINEMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SENICAPOC	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SERTRALINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SGS-742	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SIPONIMOD	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SODIUM BENZOATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SODIUM PENTABORATE PENTAHYDRATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SOLIFENACIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SOVATELITIDE	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SPG-302	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SSR180711	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
T-817 MALEATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TACROLIMUS	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TADALAFIL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TALSACLIDINE FUMARATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TIDEGLUSIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TILAVONEMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TREBANANIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TREHALOSE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TROCULEUCEL	Cell therapy	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TRORILUZOLE	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
VAFIDEMSTAT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
VALACYCLOVIR	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
VANUTIDE CRIDIFICAR	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
VARENICLINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
VAROGLUTAMSTAT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
WAX, EMULSIFYING	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ZAGOCIGUAT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ZAGOTENEMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ZATOLMILAST	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ADERBASIB Repurposing	Small molecule	Phase II	Emerging	50	—	DGIdb	—
BIHELICAL APOA-I MIMETIC PEPTIDE 5A Repurposing	Small molecule	Phase II	Emerging	50	—	DGIdb	—
COMPOUND 25 [PMID: 18068976] Repurposing	Small molecule	Phase II	Emerging	50	—	DGIdb	—
GI254023X Repurposing	Small molecule	Phase II	Emerging	50	—	DGIdb	—
HUPERZINE A Repurposing	Small molecule	Phase II	Emerging	50	—	DGIdb	—
INCB7839 Repurposing	Small molecule	Phase II	Emerging	50	—	DGIdb	—
ALPRENOLOL Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
AMIFLOXACIN Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
BROLAMFETAMINE Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
CARZENIDE Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
DIFLOXACIN Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
DIMECAMINE Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
ELLAGIC ACID Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
ENISOPROST Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
FENCAMFAMIN Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
FLEROXACIN Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
IDOXIFENE Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
LYSERGIDE Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
MERAFLOXACIN Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
TENAMFETAMINE Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
ZIDAPAMIDE Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
ALEPLASININ	Small molecule	Phase I	Emerging	40	—	Open Targets, ChEMBL	ChEMBL Open Targets
BROMOCRIPTINE	Small molecule	Phase I	Emerging	40	—	Open Targets, ChEMBL	ChEMBL Open Targets
DEXMEDETOMIDINE	Small molecule	Phase I	Emerging	40	—	Open Targets, ChEMBL	ChEMBL Open Targets
ISOTRETINOIN	Small molecule	Phase I	Emerging	40	—	Open Targets, ChEMBL	ChEMBL Open Targets
LIPOIC ACID, ALPHA	Small molecule	Phase I	Emerging	40	—	Open Targets, ChEMBL	ChEMBL Open Targets
LORAZEPAM	Small molecule	Phase I	Emerging	40	—	Open Targets, ChEMBL	ChEMBL Open Targets
SALSALATE	Small molecule	Phase I	Emerging	40	—	Open Targets, ChEMBL	ChEMBL Open Targets
(+/-)NICOTINE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
2-(AMINOMETHYL)PHENOL ACETATE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
5-(6-BENZOTHIAZOLYLMETHYLENE)-3,5-DIHYDRO-2-(((1S)-1-(METHOXYMETHYL)-3-METHYLBUTYL)AMINO)-4H-IMIDAZOL-4-ONE, (5Z)-	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ALUMINUM HYDROXIDE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
APABETALONE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ASCORBIC ACID	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
AUS-131	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
AVL-3288	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
AZD-1080	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
AZD-3839	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
BEGACESTAT	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
BIIB-080	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
BMS-984923	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
BRILAROXAZINE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
BRIVARACETAM	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CENTELLA ASIATICA EXTRACT	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CHEMBL106	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL1200904	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL1201066	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL1503	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL2030434	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL2087337	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL32	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL64391	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHOLINE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CLOFUTRIBEN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CP-609754	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CURCUMIN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CYCLOPHOSPHAMIDE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
DABIGATRAN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
DAPAGLIFLOZIN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
DASATINIB ANHYDROUS	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
DRINABANT	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
E-2212	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
EFAVIRENZ	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
EMTRICITABINE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
EMTRICITABINE, (+/-)-	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ETANERCEPT	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
FELCISETRAG	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
FOSGEMCITABINE PALABENAMIDE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
FOSGONIMETON SODIUM	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
GALCANEZUMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
GINSENG, ASIAN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
GSI-136	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
GSK-2647544	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
GSK933776	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
INSULIN ASPART	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
IRSENONTRINE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
J147	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
LATOZINEMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
LETEPRINIM POTASSIUM	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
LY-2599666	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
LY-2811376	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
MEBUFOTENIN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
METFORMIN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
MGS-0210	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
MIDODRINE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
MK-2461	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
NERVE GROWTH FACTOR	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
NIACIN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
OXALOACETATE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
OXYLANTHANUM CARBONATE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
PALOMID-529	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
PEPINEMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
PF-03654746	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
PF-04995274	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
PF-06648671	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
PF-06751979	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
PROBUCOL	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
SCOPOLAMINE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
SOR-C13	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
SUVN-D4010	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
TAK-071	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
TENOFOVIR ALAFENAMIDE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
TT-301	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
UBIDECARENONE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
VORINOSTAT	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ACETAMINOPHEN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ADUCANUMAB	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ALVAMELINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
AZ2858	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
BENZGALANTAMINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
BENZGALANTAMINE GLUCONATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
BEROTRALSTAT HYDROCHLORIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
BIFEMELANE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
BIMATOPROST	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
BUNTANETAP TARTRATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
CHEMBL10316	Small molecule	Preclinical	Emerging	15	—	ChEMBL	ChEMBL Open Targets
CHEMBL1201168	Small molecule	Preclinical	Emerging	15	—	ChEMBL	ChEMBL Open Targets
CHEMBL457	Small molecule	Preclinical	Emerging	15	—	ChEMBL	ChEMBL Open Targets
CHEMBL773	Small molecule	Preclinical	Emerging	15	—	ChEMBL	ChEMBL Open Targets
CX-717	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
DEBAMESTROCEL	Cell therapy	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
DONANEMAB	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
DONEPEZIL	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
FISH OIL	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
FLORBETABEN F18	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
FLORQUINITAU F18	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
FLORTAUCIPIR F 18	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
FLUTEMETAMOL F 18	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
FLUVASTATIN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
GABAPENTIN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
GLYCOPYRRONIUM BROMIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
GONADORELIN	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
GONADORELIN ACETATE	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
GT-2016	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
GUANFACINE HYDROCHLORIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
GV-971	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
GYKI-52466	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
HUMAN IMMUNOGLOBULIN G	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
HUPERZINE A	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ICLEPERTIN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
INSULIN LISPRO	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
IOFLUPANE I 123	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
LAZUCIRNON	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
LAZUCIRNON HYDROCHLORIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
LECANEMAB	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
LISDEXAMFETAMINE DIMESYLATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
LOVASTATIN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
MDL-28170	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
METHYLPHENIDATE HYDROCHLORIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
METRELEPTIN	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
MEVIDALEN HYDROXYBENZOATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
MILACEMIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
N-METHYL-D-ASPARTIC ACID (NMDA)	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
NABIXIMOLS	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
NICERGOLINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
OLANZAPINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
PIRACETAM	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
PITAVASTATIN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
PRADEMAGENE ZAMIKERACEL	Gene therapy	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
QUETIAPINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
RAZPIPADON	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ROSUVASTATIN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
SIBOPIRDINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
SIBOPIRDINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
SIMUFILAM HYDROCHLORIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TACRINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TENILSETAM	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
THIAZOLIDINEDIONE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets

Drug	Type	Phase	Evidence	Score	Trials & literature	Sources	Links
DONEPEZIL HYDROCHLORIDE	Small molecule	Approved	Strong	100	2 Meta-analysis 31 Trial pubs 23 RCT View evidence Published literature Meta-analysis The role of tonifying kidney decoction and acupuncture in the treatment of Alzheimer's disease: A network meta-analysis (Medicine, 2022) Meta-analysis A systematic review of the efficacy of donepezil hydrochloride combined with nimodipine on treating vascular dementia (Medicine, 2022) Clinical trial publication Effect of Social Restriction Due to the COVID-19 Pandemic on Activity of Daily Living and Disease Severity of Patients With Alzheimer Disease: Sub-analysis of a Double-blinded Noninferiority Study of Donepezil Patches and Donepezil Tablets (Alzheimer disease and associated disorders, 2025) Clinical trial publication Effect of Social Isolation Due to the COVID-19 Pandemic on Cognitive Dysfunction of Patients With Alzheimer Disease: Subanalysis of Double-blinded Noninferiority Study of Donepezil Patches and Donepezil Tablets (Alzheimer disease and associated disorders, 2024) Clinical trial publication Clinical observation on treatment of Alzheimer's disease with Sun's scalp-abdominal acupuncture combined with donepezil hydrochloride (Zhen ci yan jiu = Acupuncture research, 2024) Clinical trial publication Effects of pressing moxibustion at Baihui (GV 20) and Guanyuan (CV 4) on cognitive impairment and serum levels of Aβ(1-42), tau, P-tau in patients with mild to moderate Alzheimer's disease (Zhongguo zhen jiu = Chinese acupuncture & moxibustion, 2024) Clinical trial publication Effect of acupuncture at the acupoints for Yizhi Tiaoshen on the functional connectivity between the hippocampus and the brain in the patients with Alzheimer's disease (Zhongguo zhen jiu = Chinese acupuncture & moxibustion, 2023) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
FLORBETAPIR F 18	Small molecule	Approved	Strong	100	3 Trial pubs 3 RCT View evidence Published literature Clinical trial publication TRAILBLAZER-ALZ 4: A phase 3 trial comparing donanemab with aducanumab on amyloid plaque clearance in early, symptomatic Alzheimer's disease (Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025) Clinical trial publication A high-glycemic diet is associated with cerebral amyloid burden in cognitively normal older adults (The American journal of clinical nutrition, 2017) Clinical trial publication Physical Activity and Amyloid-β Brain Levels in Elderly Adults with Intact Cognition and Mild Cognitive Impairment (Journal of the American Geriatrics Society, 2015) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
GALANTAMINE HYDROBROMIDE	Small molecule	Approved	Strong	100	3 Trial pubs 3 RCT View evidence Published literature Clinical trial publication A prospective, double-blind, community-controlled comparison of three doses of galantamine in the treatment of mild to moderate Alzheimer's disease in a Korean population (Clinical therapeutics, 2004) Clinical trial publication The clinical efficacy and safety of galantamine in the treatment of Alzheimer's disease (CNS spectrums, 2004) Clinical trial publication The cognitive benefits of galantamine are sustained for at least 36 months: a long-term extension trial (Archives of neurology, 2004) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
MEMANTINE HYDROCHLORIDE	Small molecule	Approved	Strong	100	4 Trial pubs 3 RCT View evidence Published literature Clinical trial publication [Tolerability and efficacy of the long-term administration of memantine hydrochloride (Memary®) in patients with moderate to severe Alzheimer's disease] (Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics, 2014) Clinical trial publication Treatment with cholinesterase inhibitors and memantine of patients in the Alzheimer's Disease Neuroimaging Initiative (Archives of neurology, 2011) Clinical trial publication Investigation of the pharmacokinetic and pharmacodynamic interactions between memantine and glyburide/metformin in healthy young subjects: a single-center, multiple-dose, open-label study (Clinical therapeutics, 2005) Clinical trial publication Memantine hydrochloride: pharmacological and clinical profile (Drugs of today (Barcelona, Spain : 1998), 2004) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
RIVASTIGMINE	Small molecule	Approved	Strong	100	42 Cochrane 45 Meta-analysis 163 Trial pubs 97 RCT View evidence Published literature Cochrane review Cost-effectiveness of traditional and novel neurotherapeutic agents for Alzheimer's disease: A systematic review (Journal of Alzheimer's disease : JAD, 2026) Cochrane review Comparative safety of cholinesterase inhibitors and memantine for dementia: a protocol for a network meta-analysis of randomized controlled trials (Systematic reviews, 2025) Cochrane review Rapid health technology assessment of galantamine for the treatment of Alzheimer's disease: A review (Medicine, 2025) Cochrane review Effects of rivastigmine on gait in patients with neurodegenerative disorders: A systematic review and meta-analysis (PloS one, 2024) Cochrane review Effect of long-term pharmacological treatments on Alzheimer disease: A systematic review and network meta-analysis (Medicine, 2024) Meta-analysis Bridging the gap: Efficacy of combined therapies for cognitive, behavioral, and functional outcomes in Alzheimer's disease - results from a systematic review and network meta-analysis (Journal of Alzheimer's disease : JAD, 2025) Meta-analysis Evaluating the efficacy and safety of Alzheimer's disease drugs: A meta-analysis and systematic review (Medicine, 2024) Meta-analysis Safety and efficacy of acetylcholinesterase inhibitors for Alzheimer's disease: A systematic review and meta-analysis (Advances in clinical and experimental medicine : official organ Wroclaw Medical University, 2024) Clinical trial publication Efficacy and safety of a novel, extended-release rivastigmine transdermal patch (TW-4752N) in patients with Alzheimer's disease: A 24-week randomized, double-blind trial with a 28-week open-label extension (Journal of Alzheimer's disease : JAD, 2026) Clinical trial publication Comparative Bioavailability Study of a Novel Multi-Day Patch Formulation of Rivastigmine (Twice Weekly) with Exelon® Transdermal Patch (Daily)- A Randomized Clinical Trial (Current Alzheimer research, 2022) Clinical trial publication Rivastigmine improves dual-task gait velocity in patients with Alzheimer's disease (BMC neurology, 2021) Clinical trial publication Sixteen-Week Interventional Study to Evaluate the Clinical Effects and Safety of Rivastigmine Capsules in Chinese Patients with Alzheimer's Disease (Journal of Alzheimer's disease : JAD, 2019) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
ACETYLCYSTEINE	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
ARIPIPRAZOLE	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
BREXPIPRAZOLE	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
CRENEZUMAB	Biologic	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
DEXTROMETHORPHAN	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
DOCONEXENT	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
DOXYCYCLINE	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
ESCITALOPRAM	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
FOLIC ACID	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
GANTENERUMAB	Biologic	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
HALOPERIDOL	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
IBUPROFEN	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
INDOMETHACIN	Small molecule	Phase III	Moderate	85	3 Cochrane 2 Meta-analysis 2 Trial pubs 1 RCT View evidence Published literature Cochrane review Non-steroidal anti-inflammatory drugs as a treatment for Alzheimer's disease: a systematic review and meta-analysis of treatment effect (Drugs & aging, 2015) Cochrane review Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's disease (The Cochrane database of systematic reviews, 2012) Cochrane review Indomethacin for the treatment of Alzheimer's disease patients (The Cochrane database of systematic reviews, 2002) Clinical trial publication No effect of one-year treatment with indomethacin on Alzheimer's disease progression: a randomized controlled trial (PloS one, 2008) Clinical trial publication Clinical trial of indomethacin in Alzheimer's disease (Neurology, 1993) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
LATREPIRDINE	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
LEUPROLIDE ACETATE	Biologic	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
LIRAGLUTIDE	Biologic	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
MODAFINIL	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
NIACINAMIDE	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
NILVADIPINE	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
PREDNISONE	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
RIFAMPIN	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
RISPERIDONE	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
ROTIGOTINE	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
SEMAGACESTAT	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
SEMAGLUTIDE	Biologic	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
SERINE	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
SOLANEZUMAB	Biologic	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
SUVOREXANT	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
TRICAPRILIN	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
UDENAFIL	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
VITAMIN E	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
XALIPRODEN	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
ALPHA-TOCOPHEROL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ATORVASTATIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
AZELIRAGON	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
BAPINEUZUMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
BARICITINIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
BEZISTERIM	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
BUNTANETAP	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
BUPROPION	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CELECOXIB	Small molecule	Phase III	Moderate	80	—	Open Targets, ChEMBL	ChEMBL Open Targets
CHEMBL109	Small molecule	Phase III	Moderate	80	—	ChEMBL	ChEMBL Open Targets
CHEMBL113	Small molecule	Phase III	Moderate	80	—	ChEMBL	ChEMBL Open Targets
CHEMBL1200711	Small molecule	Phase III	Moderate	80	—	ChEMBL	ChEMBL Open Targets
CHEMBL1200806	Small molecule	Phase III	Moderate	80	—	ChEMBL	ChEMBL Open Targets
CHEMBL1536	Small molecule	Phase III	Moderate	80	—	ChEMBL	ChEMBL Open Targets
CHEMBL218166	Small molecule	Phase III	Moderate	80	—	ChEMBL	ChEMBL Open Targets
CHEMBL542541	Small molecule	Phase III	Moderate	80	—	ChEMBL	ChEMBL Open Targets
CHOLECALCIFEROL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CITALOPRAM	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CROMOLYN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CYANOCOBALAMIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
DEUDEXTROMETHORPHAN HYDROBROMIDE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ELENBECESTAT	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ENCENICLINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ENCENICLINE HYDROCHLORIDE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ESTROGENS, CONJUGATED	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
GALANTAMINE	Small molecule	Phase III	Moderate	80	—	Open Targets, ChEMBL	ChEMBL Open Targets
GUANFACINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
HYDRALAZINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
HYDROMETHYLTHIONINE MESYLATE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ICOSAPENT	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
IDALOPIRDINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
INTEPIRDINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
LANABECESTAT	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
LEVONORGESTREL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
MASITINIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
MEMANTINE	Small molecule	Phase III	Moderate	80	—	Open Targets, ChEMBL	ChEMBL Open Targets
METHYLPHENIDATE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
MIRTAZAPINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
NABILONE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
NILOTINIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
OCTAHYDROAMINOACRIDINE SUCCINATE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
PEXIDARTINIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
PHENSERINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
PROGESTERONE	Small molecule	Phase III	Moderate	80	—	Open Targets, ChEMBL	ChEMBL Open Targets
PYRIDOXINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
QUINIDINE SULFATE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
REMTERNETUG	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ROSIGLITAZONE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
SIMUFILAM	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
SIMVASTATIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TARENFLURBIL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TAVILERMIDE	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TERTOMOTIDE	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TESTOSTERONE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TIRAPAZAMINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TRAMIPROSATE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TRAZODONE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TRONTINEMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TROSPIUM CHLORIDE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
VALILTRAMIPROSATE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
VERUBECESTAT	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
XANOMELINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ZANAPEZIL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ZOLPIDEM	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ZOPICLONE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ACITRETIN	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
ARGININE	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
ATOMOXETINE HYDROCHLORIDE	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
ATORVASTATIN CALCIUM	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
AVAGACESTAT	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
BENFOTIAMINE	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
BEXAROTENE	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
CERLAPIRDINE	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
DIVALPROEX SODIUM	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
ESTRADIOL	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
ICOSAPENT ETHYL	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
INOSITOL	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
LAMIVUDINE	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
LEVETIRACETAM	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
LITHIUM CARBONATE	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
LORNOXICAM	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
MEDROXYPROGESTERONE ACETATE	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
MIFEPRISTONE	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
NAPROXEN	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
NEFIRACETAM	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
PERINDOPRIL	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
PONEZUMAB	Biologic	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
POZANICLINE	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
PRAMIPEXOLE	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
RIFAXIMIN	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
RILUZOLE	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
ROFECOXIB	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
SAPROPTERIN	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
SARACATINIB	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
TAMIBAROTENE	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
TELMISARTAN	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
THALIDOMIDE	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
THIETHYLPERAZINE	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
2,4-DINITROPHENOL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
2-HYDROXYPROPYL-BETA-CYCLODEXTRIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ABT-126	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ABT-288	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ABT-384	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ABT-418	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ACAMPROSATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ADENOSINE TRIPHOSPHATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ALBUMIN HUMAN	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ALDESLEUKIN	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
AMILOMOTIDE	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
AMLODIPINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
AQW051	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ARUNDIC ACID	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ASPIRIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ATABECESTAT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ATUZAGINSTAT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
AZD0328	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
AZD1446	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BACLOFEN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BASMISANIL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BEPRANEMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BLARCAMESINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BLARCAMESINE HYDROCHLORIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BREXANOLONE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BRYOSTATIN 1	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BUMETANIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CANAKINUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CANDESARTAN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CANNABIDIOL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CEPEROGNASTAT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CERLAPIRDINE HYDROCHLORIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CINHYALURONATE SODIUM	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CIPROFLOXACIN	Small molecule	Phase II	Emerging	60	2 pubs View evidence CT.gov search · Cochrane · PubMed	Open Targets	ChEMBL Open Targets
CLOPIDOGREL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
COLURACETAM	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CORT 108297	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CX516	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DALZANEMDOR	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DARATUMUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DASATINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DAVUNETIDE	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DB959	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DEFERIPRONE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DEXTROMETHORPHAN HYDROBROMIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DIMETHYL FUMARATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DRONABINOL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
EDELINONTRINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ELTOPRAZINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
EMAPUNIL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
EMESTEDASTAT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
EMPAGLIFLOZIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ENRUPATINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
EPIGALOCATECHIN GALLATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ETALANETUG	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ETAZOLATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
EXENATIDE	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
FACINICLINE HYDROCHLORIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
FASUDIL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
FERULATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
FILGRASTIM	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
FK-962	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
FLUTAFURANOL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
FORALUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
FORMOTEROL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
FOSGONIMETON	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GINKGO	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GOSURANEMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GSK239512	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GTS-21	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
IBUTAMOREN MESYLATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ICAPAMESPIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
IMD-1041	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
INSULIN DETEMIR	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
INSULIN GLULISINE	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
INSULIN HUMAN	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
INTERFERON BETA-1A	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
IPENOXAZONE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ISMIDENON	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ISOFLAVONE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ISPRONICLINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LADOSTIGIL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LANDIPIRDINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LECOZOTAN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LECOZOTAN HYDROCHLORIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LEMBOREXANT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LENALIDOMIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LENOGRASTIM	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LERONLIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LOSARTAN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LY-2886721	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MARITUPIRDINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MASUPIRDINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MELATONIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
METHANESULFONYL FLUORIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
METHYLENE BLUE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
METHYLENE BLUE ANHYDROUS	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
METHYLINOSITOL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MEVIDALEN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MIBAMPATOR	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MINOCYCLINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MITOGLITAZONE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MK-0249	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MK-0752	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MK-7622	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MONTELUKAST	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MW-150	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
NEFLAMAPIMOD	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
NICOTINAMIDE RIBOSIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
NIROGACESTAT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
NITROUS OXIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
OBICETRAPIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
OLEOYLESTRONE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
OMEGA-3 FATTY ACIDS	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ORM-12741	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
OSORESNONTRINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
OSUGACESTAT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
OZANIMOD	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PALIRODEN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PEGFILGRASTIM	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PEGIPANERMIN	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PEGSEBRENATIDE	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PF-05212377	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PIMAVANSERIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PIMAVANSERIN TARTRATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PIOGLITAZONE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PIROMELATINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PLASMINOGEN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
POSDINEMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PRAZOSIN	Small molecule	Phase II	Emerging	60	1 Cochrane 1 Trial pubs 1 RCT View evidence Published literature Cochrane review Risks and benefits of current and novel drugs to treat agitation in Alzheimer's disease (Expert opinion on drug safety, 2022) Clinical trial publication Prazosin for the treatment of behavioral symptoms in patients with Alzheimer disease with agitation and aggression (The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 2009) CT.gov search · Cochrane · PubMed	Open Targets	ChEMBL Open Targets
PRX-03140	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
QS-21	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
QUERCETIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
QUINIDINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RALOXIFENE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RAMELTEON	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RASAGILINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RESEQUINIL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RESVERATROL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RILAPLADIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SABIRNETUG	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SARGRAMOSTIM	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SCYLLITOL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SELTOREXANT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SEMBRAGILINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SEMORINEMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SENICAPOC	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SERTRALINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SGS-742	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SIPONIMOD	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SIROLIMUS	Small molecule	Phase II	Emerging	60	1 Meta-analysis View evidence Published literature Meta-analysis Characterization of Altered Molecular Pathways in the Entorhinal Cortex of Alzheimer's Disease Patients and In Silico Prediction of Potential Repurposable Drugs (Genes, 2022) CT.gov search · Cochrane · PubMed	Open Targets	ChEMBL Open Targets
SODIUM BENZOATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SODIUM PENTABORATE PENTAHYDRATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SOLIFENACIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SOVATELITIDE	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SPG-302	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SSR180711	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
T-817 MALEATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TACROLIMUS	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TADALAFIL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TALSACLIDINE FUMARATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TIDEGLUSIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TILAVONEMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TREBANANIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TREHALOSE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TROCULEUCEL	Cell therapy	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TRORILUZOLE	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
VAFIDEMSTAT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
VALACYCLOVIR	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
VANUTIDE CRIDIFICAR	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
VARENICLINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
VAROGLUTAMSTAT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
WAX, EMULSIFYING	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ZAGOCIGUAT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ZAGOTENEMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ZATOLMILAST	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ALEPLASININ	Small molecule	Phase I	Emerging	40	—	Open Targets, ChEMBL	ChEMBL Open Targets
BROMOCRIPTINE	Small molecule	Phase I	Emerging	40	—	Open Targets, ChEMBL	ChEMBL Open Targets
DEXMEDETOMIDINE	Small molecule	Phase I	Emerging	40	—	Open Targets, ChEMBL	ChEMBL Open Targets
ISOTRETINOIN	Small molecule	Phase I	Emerging	40	—	Open Targets, ChEMBL	ChEMBL Open Targets
LIPOIC ACID, ALPHA	Small molecule	Phase I	Emerging	40	—	Open Targets, ChEMBL	ChEMBL Open Targets
LORAZEPAM	Small molecule	Phase I	Emerging	40	—	Open Targets, ChEMBL	ChEMBL Open Targets
SALSALATE	Small molecule	Phase I	Emerging	40	—	Open Targets, ChEMBL	ChEMBL Open Targets
(+/-)NICOTINE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
2-(AMINOMETHYL)PHENOL ACETATE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
5-(6-BENZOTHIAZOLYLMETHYLENE)-3,5-DIHYDRO-2-(((1S)-1-(METHOXYMETHYL)-3-METHYLBUTYL)AMINO)-4H-IMIDAZOL-4-ONE, (5Z)-	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ALUMINUM HYDROXIDE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
APABETALONE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ASCORBIC ACID	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
AUS-131	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
AVL-3288	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
AZD-1080	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
AZD-3839	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
BEGACESTAT	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
BIIB-080	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
BMS-984923	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
BRILAROXAZINE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
BRIVARACETAM	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CENTELLA ASIATICA EXTRACT	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CHEMBL106	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL1200904	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL1201066	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL1503	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL2030434	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL2087337	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL32	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL64391	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHOLINE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CLOFUTRIBEN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CP-609754	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CURCUMIN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CYCLOPHOSPHAMIDE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
DABIGATRAN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
DAPAGLIFLOZIN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
DASATINIB ANHYDROUS	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
DRINABANT	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
E-2212	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
EFAVIRENZ	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
EMTRICITABINE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
EMTRICITABINE, (+/-)-	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ETANERCEPT	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
FELCISETRAG	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
FOSGEMCITABINE PALABENAMIDE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
FOSGONIMETON SODIUM	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
GALCANEZUMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
GINSENG, ASIAN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
GSI-136	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
GSK-2647544	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
GSK933776	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
INSULIN ASPART	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
IRSENONTRINE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
J147	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
LATOZINEMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
LETEPRINIM POTASSIUM	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
LY-2599666	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
LY-2811376	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
MEBUFOTENIN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
METFORMIN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
MGS-0210	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
MIDODRINE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
MK-2461	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
NERVE GROWTH FACTOR	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
NIACIN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
NICOTINE	Small molecule	Phase I	Emerging	35	3 Cochrane 1 Meta-analysis 18 Trial pubs 10 RCT View evidence Published literature Cochrane review Features and outcomes of drugs for combination therapy as multi-targets strategy to combat Alzheimer's disease (Journal of ethnopharmacology, 2018) Cochrane review Efficacy and safety of nicotine on Alzheimer's disease patients (The Cochrane database of systematic reviews, 2001) Cochrane review Nicotine for Alzheimer's disease (The Cochrane database of systematic reviews, 2000) Meta-analysis [Smoking and neurological disorders] (Nihon rinsho. Japanese journal of clinical medicine, 2013) Systematic review Smoking and increased Alzheimer's disease risk: a review of potential mechanisms (Alzheimer's & dementia : the journal of the Alzheimer's Association, 2014) Clinical trial publication Radiofrequency fields, transthyretin, and Alzheimer's disease (Journal of Alzheimer's disease : JAD, 2010) Clinical trial publication PET imaging of the in vivo brain acetylcholinesterase activity and nicotine binding in galantamine-treated patients with AD (Neurobiology of aging, 2008) Clinical trial publication Changes in brain 11C-nicotine binding sites in patients with mild Alzheimer's disease following rivastigmine treatment as assessed by PET (Psychopharmacology, 2007) Clinical trial publication PET imaging of cortical 11C-nicotine binding correlates with the cognitive function of attention in Alzheimer's disease (Psychopharmacology, 2006) Clinical trial publication Nicotine and sensory memory in Alzheimer's disease: an event-related potential study (Brain and cognition, 2002) Randomized controlled trial Effects of transdermal nicotine on learning, memory, verbal fluency, concentration, and general health in a healthy sample at risk for dementia (International psychogeriatrics, 2001) Randomized controlled trial Effects of acute nicotine administration on cognitive event-related potentials in tacrine-treated and non-treated patients with Alzheimer's disease (Neuropsychobiology, 2002) CT.gov search · Cochrane · PubMed	Open Targets	ChEMBL Open Targets
OXALOACETATE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
OXYLANTHANUM CARBONATE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
PALOMID-529	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
PEPINEMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
PF-03654746	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
PF-04995274	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
PF-06648671	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
PF-06751979	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
PROBUCOL	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
SCOPOLAMINE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
SOR-C13	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
SUVN-D4010	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
TAK-071	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
TENOFOVIR ALAFENAMIDE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
TT-301	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
UBIDECARENONE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
VORINOSTAT	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ACETAMINOPHEN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ADUCANUMAB	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ALVAMELINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
AZ2858	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
BENZGALANTAMINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
BENZGALANTAMINE GLUCONATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
BEROTRALSTAT HYDROCHLORIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
BIFEMELANE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
BIMATOPROST	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
BUNTANETAP TARTRATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
CHEMBL10316	Small molecule	Preclinical	Emerging	15	—	ChEMBL	ChEMBL Open Targets
CHEMBL1201168	Small molecule	Preclinical	Emerging	15	—	ChEMBL	ChEMBL Open Targets
CHEMBL457	Small molecule	Preclinical	Emerging	15	—	ChEMBL	ChEMBL Open Targets
CHEMBL773	Small molecule	Preclinical	Emerging	15	—	ChEMBL	ChEMBL Open Targets
CX-717	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
DEBAMESTROCEL	Cell therapy	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
DONANEMAB	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
DONEPEZIL	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
FISH OIL	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
FLORBETABEN F18	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
FLORQUINITAU F18	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
FLORTAUCIPIR F 18	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
FLUTEMETAMOL F 18	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
FLUVASTATIN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
GABAPENTIN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
GLYCOPYRRONIUM BROMIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
GONADORELIN	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
GONADORELIN ACETATE	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
GT-2016	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
GUANFACINE HYDROCHLORIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
GV-971	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
GYKI-52466	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
HUMAN IMMUNOGLOBULIN G	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
HUPERZINE A	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ICLEPERTIN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
INSULIN LISPRO	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
IOFLUPANE I 123	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
LAZUCIRNON	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
LAZUCIRNON HYDROCHLORIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
LECANEMAB	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
LISDEXAMFETAMINE DIMESYLATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
LOVASTATIN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
MDL-28170	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
METHYLPHENIDATE HYDROCHLORIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
METRELEPTIN	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
MEVIDALEN HYDROXYBENZOATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
MILACEMIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
N-METHYL-D-ASPARTIC ACID (NMDA)	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
NABIXIMOLS	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
NICERGOLINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
OLANZAPINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
PIRACETAM	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
PITAVASTATIN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
PRADEMAGENE ZAMIKERACEL	Gene therapy	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
QUETIAPINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
RAZPIPADON	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ROSUVASTATIN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
SIBOPIRDINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
SIBOPIRDINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
SIMUFILAM HYDROCHLORIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TACRINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TENILSETAM	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
THIAZOLIDINEDIONE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets

Drug	Type	Phase	Evidence	Score	Trials & literature	Sources	Links
ACEBUTOLOL Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	—
ACETAZOLAMIDE Repurposing via ABCA1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ACETYLCHOLINE Repurposing via ACE	Small molecule	Approved	Strong	95	—	DGIdb	—
AMBENONIUM Repurposing via ACHE	Small molecule	Approved	Strong	95	—	DGIdb	—
AMBENONIUM CHLORIDE Repurposing via ACHE	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
AMPHETAMINE Repurposing via ABCA1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
APIGENIN Repurposing via ACHE	Small molecule	Approved	Strong	95	—	DGIdb	—
APOMORPHINE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	—
APRACLONIDINE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	—
APRACLONIDINE HYDROCHLORIDE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ARGIPRESSIN Repurposing via ACE	Small molecule	Approved	Strong	95	—	DGIdb	—
ASENAPINE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	—
ASPIRIN Repurposing via ACE	Small molecule	Approved	Strong	95	—	DGIdb	—
ATENOLOL Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	—
ATIPAMEZOLE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	—
ATORVASTATIN Repurposing via ABCA1	Small molecule	Approved	Strong	95	3 Cochrane 4 Meta-analysis 9 Trial pubs 8 RCT View evidence Published literature Cochrane review Effect of long-term pharmacological treatments on Alzheimer disease: A systematic review and network meta-analysis (Medicine, 2024) Cochrane review Statins for the treatment of dementia (The Cochrane database of systematic reviews, 2010) Cochrane review Statins for the prevention of dementia (The Cochrane database of systematic reviews, 2009) Meta-analysis The calcium-free form of atorvastatin inhibits amyloid-β(1-42) aggregation in vitro (The Journal of biological chemistry, 2022) Systematic review Alzheimer's Disease: Efficacy of Mono- and Combination Therapy. A Systematic Review (Journal of geriatric psychiatry and neurology, 2022) Clinical trial publication Atorvastatin May Correct Dyslipidemia in Adult Patients at Risk for Alzheimer's Disease Through an Anti-Inflammatory Pathway (CNS & neurological disorders drug targets, 2016) Clinical trial publication Effects of atorvastatin on cerebral blood flow in middle-aged adults at risk for Alzheimer's disease: a pilot study (Current Alzheimer research, 2012) Clinical trial publication Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe (Neurology, 2010) Clinical trial publication The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): design and baseline characteristics (Alzheimer's & dementia : the journal of the Alzheimer's Association, 2008) Clinical trial publication Change in circulating C-reactive protein is not associated with atorvastatin treatment in Alzheimer's disease (Neurological research, 2006) CT.gov search · Cochrane · PubMed	DGIdb	—
ATROPINE Repurposing via ADRA2A	Small molecule	Approved	Strong	95	—	DGIdb	—
BENAZEPRIL Repurposing via ACE	Small molecule	Approved	Strong	95	—	DGIdb	—
BENAZEPRIL HYDROCHLORIDE Repurposing via ACE	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BENAZEPRILAT Repurposing via ACE	Small molecule	Approved	Strong	95	—	DGIdb	—
BENZGALANTAMINE GLUCONATE Repurposing via ACHE	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BENZPHETAMINE Repurposing via ADRA2A	Small molecule	Approved	Strong	95	—	DGIdb	—
BETAMETHASONE Repurposing via ACHE	Small molecule	Approved	Strong	95	—	DGIdb	—
BETAXOLOL Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	—
BETHANIDINE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	—
BICALUTAMIDE Repurposing via ABCA1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
BISOPROLOL Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	—
BRIMONIDINE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	—
BRIMONIDINE TARTRATE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BROMOCRIPTINE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	—
BUMETANIDE Repurposing via ACE	Small molecule	Approved	Strong	95	—	DGIdb	—
BUPROPION HYDROCHLORIDE Repurposing via ACE	Small molecule	Approved	Strong	95	—	DGIdb	—
CABERGOLINE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	—
CANDOXATRIL Repurposing via ACE	Small molecule	Approved	Strong	95	—	DGIdb	—
CAPTOPRIL Repurposing via ACE	Small molecule	Approved	Strong	95	—	DGIdb	—
CARBACHOL Repurposing via ABCA1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CARVEDILOL Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	—
CELIPROLOL Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	—
CHLORPROMAZINE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	—
CILAZAPRIL Repurposing via ACE	Small molecule	Approved	Strong	95	—	DGIdb	—
CIPROFLOXACIN Repurposing via ABCA1	Small molecule	Approved	Strong	95	2 pubs View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL Open Targets
CLOMIPRAMINE Repurposing via ABCA1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CLONIDINE HYDROCHLORIDE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	2 Trial pubs 1 RCT View evidence Published literature Clinical trial publication Effects of Alzheimer's disease and normal aging on cerebrospinal fluid norepinephrine responses to yohimbine and clonidine (Archives of general psychiatry, 1995) Clinical trial publication Clonidine treatment of Alzheimer's disease (Archives of neurology, 1989) CT.gov search · Cochrane · PubMed	DGIdb	—
CLOPIDOGREL Repurposing via ABCA1	Small molecule	Approved	Strong	95	1 Trial pubs 1 RCT View evidence Published literature Clinical trial publication Effects of cilostazol on cognition and regional cerebral blood flow in patients with Alzheimer's disease and cerebrovascular disease: a pilot study (Geriatrics & gerontology international, 2013) CT.gov search · Cochrane · PubMed	DGIdb	—
CYCLOBENZAPRINE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	—
CYCLOSPORINE Repurposing via ABCA1	Small molecule	Approved	Strong	95	20 pubs View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
DAUNORUBICIN LIPOSOMAL Repurposing via ABCA1	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
DEBRISOQUIN Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	—
DEMECARIUM BROMIDE Repurposing via ACHE	Small molecule	Approved	Strong	95	—	DGIdb	—
DESERPIDINE Repurposing via ACE	Small molecule	Approved	Strong	95	—	DGIdb	—
DEXMEDETOMIDINE HYDROCHLORIDE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	—
DEXTROAMPHETAMINE SULFATE Repurposing via ADRA2A	Small molecule	Approved	Strong	95	—	DGIdb	—
DIAZEPAM Repurposing via ABCA1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DICHLORPHENAMIDE Repurposing via ABCA1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DIETHYLSTILBESTROL Repurposing via ABCA1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DIPIVEFRIN Repurposing via ADRA2A	Small molecule	Approved	Strong	95	—	DGIdb	—
DIPIVEFRIN HYDROCHLORIDE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
DISTIGMINE Repurposing via ACHE	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
DONEPEZIL Repurposing via ACHE	Small molecule	Approved	Strong	95	—	DGIdb	—
DONEPEZIL HYDROCHLORIDE Repurposing via ACHE	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
DOPAMINE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	—
DOXAZOSIN MESYLATE Repurposing via ADRA2A	Small molecule	Approved	Strong	95	—	DGIdb	—
DOXORUBICIN HYDROCHLORIDE Repurposing via ABCA1	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
DROXIDOPA Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	—
ECHOTHIOPHATE IODIDE Repurposing via ACHE	Small molecule	Approved	Strong	95	—	DGIdb	—
ECOTHIOPATE Repurposing via ACHE	Small molecule	Approved	Strong	95	—	DGIdb	—
EDROPHONIUM CATION Repurposing via ACHE	Small molecule	Approved	Strong	95	—	DGIdb	—
EDROPHONIUM CHLORIDE Repurposing via ACHE	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ENALAPRIL MALEATE Repurposing via ACE	Small molecule	Approved	Strong	95	—	DGIdb	—
ENALAPRILAT Repurposing via ACE	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ENALAPRILAT ANHYDROUS Repurposing via ACE	Small molecule	Approved	Strong	95	—	DGIdb	—
EPHEDRINE HYDROCHLORIDE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
EPHEDRINE SULFATE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
EPINEPHRINE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	—
EPINEPHRINE BITARTRATE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
EPIRUBICIN Repurposing via ABCA1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ERGOLOID MESYLATES Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ERGOLOID MESYLATES, USP Repurposing via ADRA2A	Small molecule	Approved	Strong	95	—	DGIdb	—
ERGOTAMINE TARTRATE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ESMOLOL Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	—
ETHOXZOLAMIDE Repurposing via ABCA1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ETOMIDATE Repurposing via ADRA2B	Small molecule	Approved	Strong	95	—	DGIdb	—
FENOFIBRATE MICRONIZED Repurposing via ABCA1	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
FENOLDOPAM Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	—
FLUMAZENIL Repurposing via ABCA1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
FLUOXETINE HYDROCHLORIDE Repurposing via ACE	Small molecule	Approved	Strong	95	—	DGIdb	—
FOSINOPRIL Repurposing via ACE	Small molecule	Approved	Strong	95	—	DGIdb	—
FOSINOPRIL SODIUM Repurposing via ACE	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
FUROSEMIDE Repurposing via ACE	Small molecule	Approved	Strong	95	—	DGIdb	—
GALANTAMINE Repurposing via ACHE	Small molecule	Approved	Strong	95	—	DGIdb	—
GALANTAMINE HYDROBROMIDE Repurposing via ACHE	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
GUANABENZ Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	—
GUANABENZ ACETATE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
GUANFACINE HYDROCHLORIDE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
GUANFACINE HYDROCHLORIDE Repurposing via ADRA2A	Small molecule	Approved	Strong	95	—	DGIdb	—
HEXAFLUORENIUM BROMIDE Repurposing via ACHE	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
HYDROCHLOROTHIAZIDE Repurposing via ACE	Small molecule	Approved	Strong	95	—	DGIdb	—
HYDROXYAMPHETAMINE HYDROBROMIDE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ILOPERIDONE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	—
IMIDAPRIL Repurposing via ACE	Small molecule	Approved	Strong	95	—	DGIdb	—
IMIPRAMINE Repurposing via ABCA1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
INDAPAMIDE Repurposing via ABCA1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
INDOMETHACIN Repurposing via ACE	Small molecule	Approved	Strong	95	—	DGIdb	—
INDOMETHACIN Repurposing via ABCA1	Small molecule	Approved	Strong	95	3 Cochrane 2 Meta-analysis 2 Trial pubs 1 RCT View evidence Published literature Cochrane review Non-steroidal anti-inflammatory drugs as a treatment for Alzheimer's disease: a systematic review and meta-analysis of treatment effect (Drugs & aging, 2015) Cochrane review Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's disease (The Cochrane database of systematic reviews, 2012) Cochrane review Indomethacin for the treatment of Alzheimer's disease patients (The Cochrane database of systematic reviews, 2002) Clinical trial publication No effect of one-year treatment with indomethacin on Alzheimer's disease progression: a randomized controlled trial (PloS one, 2008) Clinical trial publication Clinical trial of indomethacin in Alzheimer's disease (Neurology, 1993) CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL Open Targets
ISOFLUROPHATE Repurposing via ACHE	Small molecule	Approved	Strong	95	—	DGIdb	—
ISOPROTERENOL Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	—
ISOSORBIDE DINITRATE Repurposing via ABCA1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
LABETALOL Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	—
LABETALOL HYDROCHLORIDE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
LEVONORDEFRIN Repurposing via ADRA2C	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
LISINOPRIL Repurposing via ACE	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
LISINOPRIL ANHYDROUS Repurposing via ACE	Small molecule	Approved	Strong	95	—	DGIdb	—
LOFEXIDINE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	—
LOFEXIDINE HYDROCHLORIDE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
LURASIDONE HYDROCHLORIDE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	—
MAFENIDE Repurposing via ABCA1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
MAGNESIUM CHLORIDE ANHYDROUS Repurposing via ACHE	Small molecule	Approved	Strong	95	—	DGIdb	—
MALATHION Repurposing via ACHE	Small molecule	Approved	Strong	95	—	DGIdb	—
MECAMYLAMINE Repurposing via ABCA1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
MEPERIDINE HYDROCHLORIDE Repurposing via ADRA2A	Small molecule	Approved	Strong	95	—	DGIdb	—
MEPHENTERMINE SULFATE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
METHADONE HYDROCHLORIDE Repurposing via ACHE	Small molecule	Approved	Strong	95	—	DGIdb	—
METHAMPHETAMINE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	—
METHAZOLAMIDE Repurposing via ABCA1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
METHOXSALEN Repurposing via ABCA1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
METHYLDOPA ANHYDROUS Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	—
METHYLDOPATE HYDROCHLORIDE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
METOPROLOL Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	—
METOPROLOL Repurposing via ABCA1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
MIANSERIN Repurposing via ABCA1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
MILNACIPRAN Repurposing via ADRA2A	Small molecule	Approved	Strong	95	—	DGIdb	—
MINAPRINE Repurposing via ACHE	Small molecule	Approved	Strong	95	—	DGIdb	—
MINAPRINE HYDROCHLORIDE Repurposing via ACHE	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
MIRTAZAPINE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	—
MOEXIPRIL Repurposing via ACE	Small molecule	Approved	Strong	95	—	DGIdb	—
MOEXIPRIL HYDROCHLORIDE Repurposing via ACE	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
MOXISYLYTE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	—
MOXONIDINE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	—
NADOLOL Repurposing via ADRA2C	Small molecule	Approved	Strong	95	1 pubs View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
NALIDIXIC ACID Repurposing via ABCA1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
NAPHAZOLINE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	—
NAPHAZOLINE HYDROCHLORIDE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
NEBIVOLOL HYDROCHLORIDE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	—
NEOSTIGMINE Repurposing via ACHE	Small molecule	Approved	Strong	95	—	DGIdb	—
NEOSTIGMINE METHYLSULFATE Repurposing via ACHE	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
NICOTINE Repurposing via ABCA1	Small molecule	Approved	Strong	95	3 Cochrane 1 Meta-analysis 18 Trial pubs 10 RCT View evidence Published literature Cochrane review Features and outcomes of drugs for combination therapy as multi-targets strategy to combat Alzheimer's disease (Journal of ethnopharmacology, 2018) Cochrane review Efficacy and safety of nicotine on Alzheimer's disease patients (The Cochrane database of systematic reviews, 2001) Cochrane review Nicotine for Alzheimer's disease (The Cochrane database of systematic reviews, 2000) Meta-analysis [Smoking and neurological disorders] (Nihon rinsho. Japanese journal of clinical medicine, 2013) Systematic review Smoking and increased Alzheimer's disease risk: a review of potential mechanisms (Alzheimer's & dementia : the journal of the Alzheimer's Association, 2014) Clinical trial publication Radiofrequency fields, transthyretin, and Alzheimer's disease (Journal of Alzheimer's disease : JAD, 2010) Clinical trial publication PET imaging of the in vivo brain acetylcholinesterase activity and nicotine binding in galantamine-treated patients with AD (Neurobiology of aging, 2008) Clinical trial publication Changes in brain 11C-nicotine binding sites in patients with mild Alzheimer's disease following rivastigmine treatment as assessed by PET (Psychopharmacology, 2007) Clinical trial publication PET imaging of cortical 11C-nicotine binding correlates with the cognitive function of attention in Alzheimer's disease (Psychopharmacology, 2006) Clinical trial publication Nicotine and sensory memory in Alzheimer's disease: an event-related potential study (Brain and cognition, 2002) Randomized controlled trial Effects of transdermal nicotine on learning, memory, verbal fluency, concentration, and general health in a healthy sample at risk for dementia (International psychogeriatrics, 2001) Randomized controlled trial Effects of acute nicotine administration on cognitive event-related potentials in tacrine-treated and non-treated patients with Alzheimer's disease (Neuropsychobiology, 2002) CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL Open Targets
NIROGACESTAT Repurposing via APH1B	Small molecule	Approved	Strong	95	—	DGIdb	—
NIROGACESTAT HYDROBROMIDE Repurposing via APH1B	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
NITROPRUSSIDE Repurposing via ACE	Small molecule	Approved	Strong	95	—	DGIdb	—
NOREPINEPHRINE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	—
NOREPINEPHRINE BITARTRATE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
NORFLOXACIN Repurposing via ABCA1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
NORTRIPTYLINE Repurposing via ADRA2A	Small molecule	Approved	Strong	95	—	DGIdb	—
OFLOXACIN Repurposing via ABCA1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
OLANZAPINE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	—
OXYMETAZOLINE HYDROCHLORIDE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	—
OXYMETAZOLINE HYDROCHLORIDE Repurposing via ADRA2B	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
PERGOLIDE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	—
PERINDOPRIL Repurposing via ACE	Small molecule	Approved	Strong	95	—	DGIdb	—
PERINDOPRIL ARGININE Repurposing via ACE	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
PERINDOPRIL ERBUMINE Repurposing via ACE	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
PERINDOPRILAT Repurposing via ACE	Small molecule	Approved	Strong	95	—	DGIdb	—
PHENOXYBENZAMINE Repurposing via ADRA2B	Small molecule	Approved	Strong	95	—	DGIdb	—
PHENOXYBENZAMINE HYDROCHLORIDE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
PHENTOLAMINE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	—
PHENTOLAMINE MESYLATE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
PHENYLPROPANOLAMINE Repurposing via ADRA2A	Small molecule	Approved	Strong	95	—	DGIdb	—
PHENYTOIN Repurposing via ABCA1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
PHYSOSTIGMINE Repurposing via ACHE	Small molecule	Approved	Strong	95	—	DGIdb	—
PHYSOSTIGMINE SALICYLATE Repurposing via ACHE	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
PINDOLOL Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	—
PRALIDOXIME CATION Repurposing via ACHE	Small molecule	Approved	Strong	95	—	DGIdb	—
PRALIDOXIME CHLORIDE Repurposing via ACHE	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
PRASUGREL Repurposing via ABCA1	Small molecule	Approved	Strong	95	1 pubs View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
PRAVASTATIN SODIUM Repurposing via ABCA1	Small molecule	Approved	Strong	95	1 Trial pubs View evidence Published literature Clinical trial publication Reduction in levels of 24S-hydroxycholesterol by statin treatment in patients with Alzheimer disease (Archives of neurology, 2003) CT.gov search · Cochrane · PubMed	DGIdb	—
PRAZOSIN Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	—
PRAZOSIN Repurposing via ABCA1	Small molecule	Approved	Strong	95	1 Cochrane 1 Trial pubs 1 RCT View evidence Published literature Cochrane review Risks and benefits of current and novel drugs to treat agitation in Alzheimer's disease (Expert opinion on drug safety, 2022) Clinical trial publication Prazosin for the treatment of behavioral symptoms in patients with Alzheimer disease with agitation and aggression (The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 2009) CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL Open Targets
PROBUCOL Repurposing via ABCA1	Small molecule	Approved	Strong	95	1 Trial pubs 1 RCT View evidence Published literature Clinical trial publication Effects of Probucol on plasma amyloid-β transport in patients with hyperlipidemia: a 12-week randomized, double-blind, placebo-controlled trial (Lipids in health and disease, 2024) CT.gov search · Cochrane · PubMed	DGIdb	—
PROPANIDID Repurposing via ACHE	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
PROPRANOLOL HYDROCHLORIDE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
PROPYLHEXEDRINE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	—
PSEUDOEPHEDRINE POLISTIREX Repurposing via ADRA2A	Small molecule	Approved	Strong	95	—	DGIdb	—
PYRIDOSTIGMINE Repurposing via ACHE	Small molecule	Approved	Strong	95	—	DGIdb	—
PYRIDOSTIGMINE BROMIDE Repurposing via ACHE	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
QUINAPRIL Repurposing via ACE	Small molecule	Approved	Strong	95	—	DGIdb	—
QUINAPRIL HYDROCHLORIDE Repurposing via ACE	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
QUINAPRILAT Repurposing via ACE	Small molecule	Approved	Strong	95	—	DGIdb	—
RACEPINEPHRINE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	—
RAMIPRIL Repurposing via ACE	Small molecule	Approved	Strong	95	—	DGIdb	—
RAMIPRILAT Repurposing via ACE	Small molecule	Approved	Strong	95	—	DGIdb	—
RAUWOLFIA SERPENTINA Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
RAUWOLFIA SERPENTINA (USP) Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	—
REMIFENTANIL HYDROCHLORIDE Repurposing via ADRA2A	Small molecule	Approved	Strong	95	—	DGIdb	—
RESCINNAMINE Repurposing via ACE	Small molecule	Approved	Strong	95	—	DGIdb	—
RILMENIDINE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	—
RISPERIDONE Repurposing via ADRA2A	Small molecule	Approved	Strong	95	—	DGIdb	—
RIVASTIGMINE Repurposing via ACHE	Small molecule	Approved	Strong	95	—	DGIdb	—
RIVASTIGMINE TARTRATE Repurposing via ACHE	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ROSUVASTATIN Repurposing via ABCA1	Small molecule	Approved	Strong	95	1 Cochrane 1 Meta-analysis View evidence Published literature Cochrane review Statins for the prevention of dementia (The Cochrane database of systematic reviews, 2009) CT.gov search · Cochrane · PubMed	DGIdb	—
SILDENAFIL Repurposing via ACE	Small molecule	Approved	Strong	95	—	DGIdb	—
SIMVASTATIN Repurposing via ABCA1	Small molecule	Approved	Strong	95	6 Cochrane 4 Meta-analysis 16 Trial pubs 9 RCT View evidence Published literature Cochrane review Statins for the prevention of dementia (The Cochrane database of systematic reviews, 2016) Cochrane review Statins for the treatment of dementia (The Cochrane database of systematic reviews, 2010) Cochrane review Can statins prevent or help treat Alzheimer's disease? (Journal of Alzheimer's disease : JAD, 2010) Cochrane review Statins for the prevention of dementia (The Cochrane database of systematic reviews, 2009) Cochrane review Statins for the prevention of Alzheimer's disease (The Cochrane database of systematic reviews, 2001) Meta-analysis Evidence for benefit of statins to modify cognitive decline and risk in Alzheimer's disease (Alzheimer's research & therapy, 2017) Clinical trial publication Effects of Simvastatin on Plasma Amyloid-β Transport in Patients with Hyperlipidemia: A 12-Week Randomized, Double-Blind, Placebo-Controlled Trial (Journal of Alzheimer's disease : JAD, 2022) Clinical trial publication Effect of simvastatin on CSF Alzheimer disease biomarkers in cognitively normal adults (Neurology, 2017) Clinical trial publication Simvastatin ameliorate memory deficits and inflammation in clinical and mouse model of Alzheimer's disease via modulating the expression of miR-106b (Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2017) Clinical trial publication LDL-lipids from patients with hypercholesterolaemia and Alzheimer's disease are inflammatory to microvascular endothelial cells: mitigation by statin intervention (Clinical science (London, England : 1979), 2015) Clinical trial publication Longitudinal plasma amyloid beta in Alzheimer's disease clinical trials (Alzheimer's & dementia : the journal of the Alzheimer's Association, 2015) Randomized controlled trial Toward onset prevention of cognitive decline in adults with Down syndrome (the TOP-COG study): study protocol for a randomized controlled trial (Trials, 2014) CT.gov search · Cochrane · PubMed	DGIdb	—
SIROLIMUS Repurposing via ABCA1	Small molecule	Approved	Strong	95	1 Meta-analysis View evidence Published literature Meta-analysis Characterization of Altered Molecular Pathways in the Entorhinal Cortex of Alzheimer's Disease Patients and In Silico Prediction of Potential Repurposable Drugs (Genes, 2022) CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL Open Targets
SODIUM CHLORIDE Repurposing via ADRA2A	Small molecule	Approved	Strong	95	—	DGIdb	—
SOTALOL Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	—
SPIRAPRIL Repurposing via ACE	Small molecule	Approved	Strong	95	—	DGIdb	—
SPIRAPRIL HYDROCHLORIDE Repurposing via ACE	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
SULBACTAM Repurposing via ABCA1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
TACRINE Repurposing via ACHE	Small molecule	Approved	Strong	95	—	DGIdb	—
TACRINE HYDROCHLORIDE Repurposing via ACHE	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
TACROLIMUS ANHYDROUS Repurposing via ABCA1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
TAZOBACTAM Repurposing via ABCA1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
TETRAHYDROZOLINE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	—
TETRAHYDROZOLINE HYDROCHLORIDE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
THIOGUANINE Repurposing via ACHE	Small molecule	Approved	Strong	95	—	DGIdb	—
TIZANIDINE HYDROCHLORIDE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	—
TIZANIDINE HYDROCHLORIDE Repurposing via ADRA2B	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
TOLAZOLINE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	—
TOLAZOLINE HYDROCHLORIDE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
TORSEMIDE Repurposing via ACE	Small molecule	Approved	Strong	95	—	DGIdb	—
TRANDOLAPRIL Repurposing via ACE	Small molecule	Approved	Strong	95	—	DGIdb	—
TRANDOLAPRILAT Repurposing via ACE	Small molecule	Approved	Strong	95	—	DGIdb	—
TRAZODONE Repurposing via ADRA2A	Small molecule	Approved	Strong	95	—	DGIdb	—
TROGLITAZONE Repurposing via ABCA1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
VORINOSTAT Repurposing via ACE	Small molecule	Approved	Strong	95	—	DGIdb	—
XYLAZINE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	—
XYLOMETAZOLINE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	—
XYLOMETAZOLINE HYDROCHLORIDE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
YOHIMBINE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	—
DARAPLADIB Repurposing via ABCA1	Small molecule	Phase III	Moderate	70	—	ChEMBL	ChEMBL Open Targets
FENRETINIDE Repurposing via ABCA1	Small molecule	Phase III	Moderate	70	—	ChEMBL	ChEMBL Open Targets
ADERBASIB Repurposing via ADAM10	Small molecule	Phase II	Emerging	50	—	DGIdb	—
BIHELICAL APOA-I MIMETIC PEPTIDE 5A Repurposing via ABCA1	Small molecule	Phase II	Emerging	50	—	DGIdb	—
COMPOUND 25 [PMID: 18068976] Repurposing via ADAM10	Small molecule	Phase II	Emerging	50	—	DGIdb	—
GI254023X Repurposing via ADAM10	Small molecule	Phase II	Emerging	50	—	DGIdb	—
HUPERZINE A Repurposing via ACHE	Small molecule	Phase II	Emerging	50	—	DGIdb	—
INCB7839 Repurposing via ADAM10	Small molecule	Phase II	Emerging	50	—	DGIdb	—
ALPRENOLOL Repurposing via ABCA1	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
AMIFLOXACIN Repurposing via ABCA1	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
BROLAMFETAMINE Repurposing via ABCA1	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
CARZENIDE Repurposing via ABCA1	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
DIFLOXACIN Repurposing via ABCA1	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
DIMECAMINE Repurposing via ABCA1	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
ELLAGIC ACID Repurposing via ABCA1	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
ENISOPROST Repurposing via ABCA1	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
FENCAMFAMIN Repurposing via ABCA1	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
FLEROXACIN Repurposing via ABCA1	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
IDOXIFENE Repurposing via ABCA1	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
LYSERGIDE Repurposing via ABCA1	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
MERAFLOXACIN Repurposing via ABCA1	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
TENAMFETAMINE Repurposing via ABCA1	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
ZIDAPAMIDE Repurposing via ABCA1	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets

Natural Products

112 natural products with the same evidence schema as repurposed drugs — registry trials, PubMed literature, and reference links (pipeline-ranked)

Reference lookups: GreenMedInfo · Examine.com

Drug	Type	Phase	Evidence	Score	Trials & literature	Sources	Links
Vitamin D3 Natural product Meta Analysis, Review Effect of berberine on cognitive function and β-amyloid precursor prote… Meta Analysis, Review Effects of selenium supplementation in patients with mild cognitive imp… Meta Analysis, Review Neuroprotective effects and possible mechanisms of berberine in animal…	Nutraceutical	Preclinical	Emerging	10	2 Trial pubs View evidence CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Vitamin E Natural product Meta Analysis Alzheimer disease is associated with a low concentration of serum vitam… Human Study A combined micronutrient dietary supplement should be considered in the… Human Study A multi-vitamin/nutrient formula has therapeutic value in early-stage A…	Nutraceutical	Preclinical	Emerging	10	16 Meta-analysis View evidence CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Folate Natural product Meta Analysis, Review Effects of selenium supplementation in patients with mild cognitive imp… Meta Analysis, Review Neuroprotective effects and possible mechanisms of berberine in animal… Meta Analysis, Review Ginkgo biloba is potentially beneficial for the improvement of cognitiv…	Nutraceutical	Preclinical	Emerging	10	324 pubs View evidence CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Vitamin B12 Natural product Meta Analysis, Review Effects of selenium supplementation in patients with mild cognitive imp… Meta Analysis, Review Neuroprotective effects and possible mechanisms of berberine in animal… Meta Analysis, Review Ginkgo biloba is potentially beneficial for the improvement of cognitiv…	Nutraceutical	Preclinical	Emerging	10	6 Meta-analysis 5 RCT View evidence CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Omega-3 Fatty Acids Natural product Meta Analysis The Relationship of Omega-3 Fatty acids with dementia and Cognitive Dec… Human Study A combined micronutrient dietary supplement should be considered in the… Human Study Boswellic acids improve clinical cognitive scores and reduce systemic i…	Nutraceutical	Preclinical	Emerging	10	8 Cochrane View evidence CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
N-Acetylcysteine Natural product Systematic review N-Acetylcysteine in Neurological Disorders: A Systematic Review of Clin… Human Study A multi-vitamin/nutrient formula has therapeutic value in early-stage A… Human Study A multi-vitamin/nutrient formula has therapeutic value in moderate-stag…	Amino acid	Preclinical	Emerging	10	No indexed hits View evidence Published literature Systematic review N-Acetylcysteine in Neurological Disorders: A Systematic Review of Clinical and Translational Evidence Across Seven Disorders (International journal of molecular sciences, 2026) CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Ginger Natural product Cochrane review Zingiber officinale ameliorates Alzheimer's disease and Cognitive Impai…	Botanical	Preclinical	Emerging	10	1 Cochrane View evidence Published literature Cochrane review Zingiber officinale ameliorates Alzheimer's disease and Cognitive Impairments: Lessons from preclinical studies (Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2021) CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Vitamin C Natural product Clinical trial publication Antioxidants for Alzheimer disease: a randomized clinical trial with ce… Clinical trial publication Treatment of Alzheimer's disease with a cholinesterase inhibitor combin… Clinical trial publication Dementia and Alzheimer's disease in community-dwelling elders taking vi…	Nutraceutical	Preclinical	Emerging	10	9 Meta-analysis 6 Trial pubs View evidence Published literature Clinical trial publication Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures (Archives of neurology, 2012) Clinical trial publication Treatment of Alzheimer's disease with a cholinesterase inhibitor combined with antioxidants (Neuro-degenerative diseases, 2010) Clinical trial publication Dementia and Alzheimer's disease in community-dwelling elders taking vitamin C and/or vitamin E (The Annals of pharmacotherapy, 2005) Clinical trial publication Antioxidants in Alzheimer's disease-vitamin C delivery to a demanding brain (Journal of Alzheimer's disease : JAD, 2003) Clinical trial publication Plasma antioxidants are similarly depleted in mild cognitive impairment and in Alzheimer's disease (Neurobiology of aging, 2003) CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Lutein Natural product Human Study Aerobic fitness may have a positive influence on protection of brain ev… Human Study High adherence to a Mediterranean diet was associated with better cogni… Human Study High homocysteine levels may be associated with the pathogenesis of neu…	Nutraceutical	Preclinical	Emerging	10	No indexed hits View evidence CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Lycopene Natural product A narrative review on the potential of tomato and lycopene for the prev…	Food compound	Preclinical	Emerging	10	No indexed hits View evidence CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Olive Oil Natural product Meta-analysis The role of the Mediterranean diet in reducing the risk of cognitive im… Systematic review Dietary Intake, Mediterranean and Nordic Diet Adherence in Alzheimer's… Systematic review Alzheimer's Disease May Benefit from Olive Oil Polyphenols: A Systemati…	Nutraceutical	Preclinical	Emerging	10	1 Meta-analysis 4 Trial pubs View evidence Published literature Meta-analysis The role of the Mediterranean diet in reducing the risk of cognitive impairement, dementia, and Alzheimer's disease: a meta-analysis (GeroScience, 2025) Systematic review Dietary Intake, Mediterranean and Nordic Diet Adherence in Alzheimer's Disease and Dementia: A Systematic Review (Nutrients, 2025) Systematic review Alzheimer's Disease May Benefit from Olive Oil Polyphenols: A Systematic Review on Preclinical Evidence Supporting the Effect of Oleocanthal on Amyloid-β Load (Current neuropharmacology, 2025) Systematic review The Mediterranean, Dietary Approaches to Stop Hypertension (DASH), and Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) Diets Are Associated with Less Cognitive Decline and a Lower Risk of Alzheimer's Disease-A Review (Advances in nutrition (Bethesda, Md.), 2019) CT.gov search · Cochrane · PubMed	GreenMedInfo	GreenMedInfo
Curcumin Natural product Randomized controlled trial Dietary Supplementation with Curcumin Reduce Circulating Levels of Glyc… Randomized controlled trial Six-month randomized, placebo-controlled, double-blind, pilot clinical… Randomized controlled trial Curcumin effects on blood lipid profile in a 6-month human study	Food compound	Preclinical	Emerging	7	3 RCT View evidence Published literature Randomized controlled trial Dietary Supplementation with Curcumin Reduce Circulating Levels of Glycogen Synthase Kinase-3β and Islet Amyloid Polypeptide in Adults with High Risk of Type 2 Diabetes and Alzheimer's Disease (Nutrients, 2020) Randomized controlled trial Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease (Journal of clinical psychopharmacology, 2008) Randomized controlled trial Curcumin effects on blood lipid profile in a 6-month human study (Pharmacological research, 2007) CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Alpha-Lipoic Acid Natural product Clinical trial publication A randomized placebo-controlled pilot trial of omega-3 fatty acids and… Clinical trial publication Antioxidants for Alzheimer disease: a randomized clinical trial with ce… Clinical trial publication Down syndrome and dementia: a randomized, controlled trial of antioxida…	Nutraceutical	Preclinical	Emerging	7	4 Trial pubs 3 RCT View evidence Published literature Clinical trial publication A randomized placebo-controlled pilot trial of omega-3 fatty acids and alpha lipoic acid in Alzheimer's disease (Journal of Alzheimer's disease : JAD, 2014) Clinical trial publication Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures (Archives of neurology, 2012) Clinical trial publication Down syndrome and dementia: a randomized, controlled trial of antioxidant supplementation (American journal of medical genetics. Part A, 2011) Clinical trial publication Alpha-lipoic acid as a new treatment option for Alzheimer's disease--a 48 months follow-up analysis (Journal of neural transmission. Supplementum, 2007) CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Melatonin Natural product Randomized controlled trial A Polymorphism Cluster at the 2q12 locus May Predict Response to Pirome… Randomized controlled trial EEG coherence and power spectra during REM sleep related to melatonin i… Randomized controlled trial Dietary Melatonin Therapy Alleviates the Lamina Cribrosa Damages in Pat…	Nutraceutical	Preclinical	Emerging	7	11 Meta-analysis 9 RCT View evidence Published literature Randomized controlled trial A Polymorphism Cluster at the 2q12 locus May Predict Response to Piromelatine in Patients with Mild Alzheimer's Disease (The journal of prevention of Alzheimer's disease, 2022) Randomized controlled trial EEG coherence and power spectra during REM sleep related to melatonin intake in mild-to-moderate Alzheimer's disease: a pilot study (The International journal of neuroscience, 2023) Randomized controlled trial Dietary Melatonin Therapy Alleviates the Lamina Cribrosa Damages in Patients with Mild Cognitive Impairments: A Double-Blinded, Randomized Controlled Study (Medical science monitor : international medical journal of experimental and clinical research, 2020) Randomized controlled trial Melatonin effects on EEG activity during non-rapid eye movement sleep in mild-to-moderate Alzheimer´s disease: a pilot study (The International journal of neuroscience, 2021) Randomized controlled trial Add-on prolonged-release melatonin for cognitive function and sleep in mild to moderate Alzheimer's disease: a 6-month, randomized, placebo-controlled, multicenter trial (Clinical interventions in aging, 2014) CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Resveratrol Natural product Meta-analysis Evidence of Clinical Efficacy and Pharmacological Mechanisms of Resvera… Human Study Application of dawn-dusk simulation at the sleep-wake transitions appea… Human Study Dose response of transcranial near infrared light stimulation on brain…	Food compound	Preclinical	Emerging	7	5 Cochrane 1 Meta-analysis 4 Trial pubs 4 RCT View evidence Published literature Meta-analysis Evidence of Clinical Efficacy and Pharmacological Mechanisms of Resveratrol in the Treatment of Alzheimer's Disease (Current Alzheimer research, 2023) CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Selenium Natural product Randomized controlled trial The LipiDiDiet trial: what does it add to the current evidence for Fort… Randomized controlled trial Probiotic and selenium co-supplementation, and the effects on clinical,… Randomized controlled trial Supranutritional Sodium Selenate Supplementation Delivers Selenium to t…	Nutraceutical	Preclinical	Emerging	7	3 Cochrane 10 RCT View evidence Published literature Randomized controlled trial The LipiDiDiet trial: what does it add to the current evidence for Fortasyn Connect in early Alzheimer's disease? (Clinical interventions in aging, 2019) Randomized controlled trial Probiotic and selenium co-supplementation, and the effects on clinical, metabolic and genetic status in Alzheimer's disease: A randomized, double-blind, controlled trial (Clinical nutrition (Edinburgh, Scotland), 2019) Randomized controlled trial Supranutritional Sodium Selenate Supplementation Delivers Selenium to the Central Nervous System: Results from a Randomized Controlled Pilot Trial in Alzheimer's Disease (Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2019) Randomized controlled trial Association of Antioxidant Supplement Use and Dementia in the Prevention of Alzheimer's Disease by Vitamin E and Selenium Trial (PREADViSE) (JAMA neurology, 2017) Randomized controlled trial Self-Reported Sleep Apnea and Dementia Risk: Findings from the Prevention of Alzheimer's Disease with Vitamin E and Selenium Trial (Journal of the American Geriatrics Society, 2016) CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Berberine Natural product Systematic review Berberine derivatives as inhibitors of acetylcholinesterase: A systemat… Systematic review Berberine for prevention of dementia associated with diabetes and its c… Systematic review Neuroprotective effects of berberine in animal models of Alzheimer's di…	Botanical	Preclinical	Emerging	7	No indexed hits View evidence Published literature Systematic review Berberine derivatives as inhibitors of acetylcholinesterase: A systematic review (Chemical biology & drug design, 2023) Systematic review Berberine for prevention of dementia associated with diabetes and its comorbidities: A systematic review (Journal of integrative medicine, 2020) Systematic review Neuroprotective effects of berberine in animal models of Alzheimer's disease: a systematic review of pre-clinical studies (BMC complementary and alternative medicine, 2019) Systematic review Advances in structural modifications and biological activities of berberine: an active compound in traditional Chinese medicine (Mini reviews in medicinal chemistry, 2011) Systematic review [Advances in the study of berberine and its derivatives] (Yao xue xue bao = Acta pharmaceutica Sinica, 2008) CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Niacin Natural product Clinical trial publication Reduction in levels of 24S-hydroxycholesterol by statin treatment in pa… Human Study A multi-vitamin/nutrient formula has therapeutic value in early-stage A… Human Study A multi-vitamin/nutrient formula has therapeutic value in moderate-stag…	Nutraceutical	Preclinical	Emerging	7	1 Trial pubs View evidence Published literature Clinical trial publication Reduction in levels of 24S-hydroxycholesterol by statin treatment in patients with Alzheimer disease (Archives of neurology, 2003) CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Saffron Natural product Human Study Administration of saffron capsules was comparable with memantine in red…	Botanical	Preclinical	Emerging	7	30 pubs View evidence CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Probiotics Natural product Cochrane review The microbiota-gut-brain axis in mild cognitive impairment and Alzheime… Cochrane review Effectiveness of probiotic supplements on cognitive function in mild co… Cochrane review Efficacy of probiotic supplementation in influencing cognitive function…	Probiotic	Preclinical	Emerging	7	10 Cochrane 5 RCT View evidence Published literature Cochrane review The microbiota-gut-brain axis in mild cognitive impairment and Alzheimer's disease: a scoping review of human studies (Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026) Cochrane review Effectiveness of probiotic supplements on cognitive function in mild cognitive impairment and Alzheimer's disease: A meta-analysis of randomized controlled trials (General hospital psychiatry, 2025) Cochrane review Efficacy of probiotic supplementation in influencing cognitive function in Alzheimer's disease: A systematic review and meta-analysis (Journal of food science, 2025) Cochrane review Effect of probiotics on cognitive function in adults with mild cognitive impairment or Alzheimer's disease: A meta-analysis of randomized controlled trials (Medicina clinica, 2024) Cochrane review Probiotic supplements are effective in people with cognitive impairment: a meta-analysis of randomized controlled trials (Nutrition reviews, 2023) Randomized controlled trial Efficacy and Safety of MT104, A Dietary Supplement Based on Cuscuta Seeds and Heat-Killed Probiotics, on Cognitive Function in Patients with Mild Cognitive Impairment: A 12-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial (Journal of medicinal food, 2025) Randomized controlled trial Effect of the probiotic Escherichia coli Nissle 1917 on serum levels of NADPH oxidase-2 and lipopolysaccharide in patients with Alzheimer's disease (Journal of Alzheimer's disease : JAD, 2025) Randomized controlled trial The effects of probiotic supplements on oxidative stress and inflammation in subjects with mild and moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled study (Inflammopharmacology, 2024) Randomized controlled trial Efficacy of Probiotic Supplements on Brain-Derived Neurotrophic Factor, Inflammatory Biomarkers, Oxidative Stress and Cognitive Function in Patients with Alzheimer's Dementia: A 12-Week Randomized, Double-Blind Active-Controlled Study (Nutrients, 2023) Randomized controlled trial Probiotic intervention benefits multiple neural behaviors in older adults with mild cognitive impairment (Geriatric nursing (New York, N.Y.), 2023) CT.gov search · Cochrane · PubMed	GreenMedInfo	GreenMedInfo
L-Carnitine Natural product Human Study A multi-vitamin/nutrient formula has therapeutic value in early-stage A… Human Study A multi-vitamin/nutrient formula has therapeutic value in moderate-stag…	Amino acid	Preclinical	Emerging	7	—	GreenMedInfo	PubChem GreenMedInfo
Egcg Natural product Human Study Antioxidant beverages could be used as a natural complementary therapy… Human Study Green tea improves cognitive function through reducing AD-pathology and…	Food compound	Preclinical	Emerging	7	—	GreenMedInfo	PubChem GreenMedInfo
Reishi Natural product	Mushroom	Preclinical	Emerging	7	—	GreenMedInfo	GreenMedInfo
Boswellia Natural product Human Study Boswellic acids improve clinical cognitive scores and reduce systemic i…	Botanical	Preclinical	Emerging	7	—	GreenMedInfo	PubChem GreenMedInfo
Bacopa Natural product Human Study Efficacy of Bacopa monnieri and donepezil in Alzheimer's disease a…	Ayurvedic	Preclinical	Emerging	7	—	GreenMedInfo	GreenMedInfo
Fenugreek Natural product Human Study Fenugreek seed extract supplementation in AD patients shows promising p…	Botanical	Preclinical	Emerging	7	—	GreenMedInfo	GreenMedInfo
Ginkgo Biloba Natural product Meta Analysis, Review Ginkgo biloba preparations plus donepezil can improve clinical effectiv… Meta Analysis, Review Ginkgo biloba is potentially beneficial for the improvement of cognitiv… Meta Analysis Meta-analytic findings suggested overall benefits of EGb 761 for stabil…	Botanical	Preclinical	Emerging	2	—	GreenMedInfo	GreenMedInfo
Terazosin Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Yohimbine Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Indoramin Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Phentolamine Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Prazosin Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Tamsulosin Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Clonidine Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Apraclonidine Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Doxazosin Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Mianserin Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Akuammigine Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Rauwolscine Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Corynantheine Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Oxymetazoline Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Lisinopril Anhydrous Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Enalaprilat Anhydrous Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Captopril Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Enalapril Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Quinapril Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Quinaprilat Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Moexipril Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Neostigmine Bromide Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Ranitidine Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Physostigmine Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Huprine X Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Edrophonium Bromide Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
1,2,3,4-tetrahydroacridin-9-ylamine Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Huperzine a Natural product Meta Analysis Huperzine A appears to have beneficial effects on improvement of cognit… Meta Analysis Huperzine A is a well-tolerated drug that could significantly improve c… Human Study A supplement containing huperzine A and curcumin in dementia patients a…	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Ilomastat Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Atipamezole Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Vancomycin Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Desglymidodrine Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Phenylpropanolamine Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Dexniguldipine Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Niguldipine Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Huperzine Natural product Meta Analysis Huperzine A appears to have beneficial effects on improvement of cognit… Meta Analysis Huperzine A is a well-tolerated drug that could significantly improve c… Human Study A supplement containing huperzine A and curcumin in dementia patients a…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Coconut Oil Natural product Human Study Coconut oil was found to be beneficial in female patients with Alzheime… Human Study Isocaloric coconut oil enriched Mediterranean diet seems to improve cog… Human Study Medium Chain Triglycerides (coconut fat) increase cognitive performance…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Carotenoids Natural product Human Study A combined micronutrient dietary supplement should be considered in the… Human Study Maintaining higher concentrations of lutein in respect to plasma lipids…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Caffeine Natural product Human Study Caffeine given at breakfast significantly stimulated ketone production… Human Study, Review, Transgenic Animal Study Caffeine in coffee can prevent and help brain function in Alzheimer&#03…	Food compound	Preclinical	Emerging	0	—	GreenMedInfo	PubChem GreenMedInfo
Citicoline Natural product Human Study Citicoline in the treatment of the mild cognitive impairment syndrome.	Food compound	Preclinical	Emerging	0	—	GreenMedInfo	PubChem GreenMedInfo
Strawberry Natural product Human Study Consumption of strawberries and foods rich in vitamin C, pelargonidin,… Human Study Early intervention in cognitive aging with strawberry supplementation.	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
B-Complex Natural product Human Study High homocysteine levels may be associated with the pathogenesis of neu… Human Study Higher levels of homocysteine and lower levels of folate and B vitamins…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Flavonoids Natural product Human Study Consumption of strawberries and foods rich in vitamin C, pelargonidin,… Human Study Higher dietary intakes of flavonols may be associated with reduced risk…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Sage Natural product	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Rosemary Natural product Meta Analysis, Review Cognition enhancing effect of rosemary (Rosmarinus officinalis L.) in l…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Coffee Natural product Meta Analysis, Review Higher coffee consumption is associated with reduced risk for Alzheimer… Human Study, Review, Transgenic Animal Study Caffeine in coffee can prevent and help brain function in Alzheimer&#03…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Nobiletin Natural product Human In Vitro, Human Study Potential of nobiletin against Alzheimer's disease through inhibit…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
SAMe (S-Adenosylmethionine) Natural product Human Study A multi-vitamin/nutrient formula has therapeutic value in early-stage A… Human Study A multi-vitamin/nutrient formula has therapeutic value in moderate-stag…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Lactoferrin Natural product Human Study A pilot study on the effect of lactoferrin on Alzheimer's disease… Human Study Decreased salivary lactoferrin levels are specific to Alzheimer's…	Food compound	Preclinical	Emerging	0	—	GreenMedInfo	PubChem GreenMedInfo
Polyunsaturated Fatty Acids (PUFAs) Natural product Meta Analysis The Relationship of Omega-3 Fatty acids with dementia and Cognitive Dec… Human Study Boswellic acids improve clinical cognitive scores and reduce systemic i… Human Study High intake of polyunsaturated fatty acids (PUFA) and monounsaturated f…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Coconut Natural product Human Study Coconut oil was found to be beneficial in female patients with Alzheime… Human Study Isocaloric coconut oil enriched Mediterranean diet seems to improve cog… Human Study Medium Chain Triglycerides (coconut fat) increase cognitive performance…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Medium Chain Triglycerides Natural product Human Study Effects of a medium-chain triglyceride-based ketogenic formula on cogni… Human Study Medium Chain Triglycerides (coconut fat) increase cognitive performance…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Lemon Balm Natural product	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo

Alterations and therapeutics are aggregated from public databases (Open Targets, HPO, ChEMBL, DGIdb, and others). Natural agents are candidates from OSMF narrative reviews on opensourcemed.info/chronic-disease.html — not approved treatments. This page is for research orientation only — not medical advice.

Alzheimer's Disease and Other Dementias

Disease overview

Remission & chronicity

Alterations

Therapeutics

Natural Products

Part of the Open Source Medicine Foundation Network